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ABSTRACT 
BRITTANY D. WRIGHT:  Lipid kinase regulation of nociceptive signaling and 
sensitization: Implications for analgesic drug development 
(Under the direction of Mark Zylka) 
 
Chronic pain affects approximately 35% of American adults resulting in 
annual treatment costs over $600 billion.  Unfortunately, current therapeutics have 
harmful side effects while only providing partial relief, highlighting the need for novel 
therapeutic targets for analgesic drug development.  Neuropathic pain and 
inflammatory pain are the two most common forms of chronic pain in humans.  In 
these conditions, nerve injury and inflammation lead to the release of pronociceptive 
molecules that signal through pronociceptive (pain-promoting) G protein-coupled 
receptors (GPCRs) and ion channels to sensitize nociceptive neurons in the dorsal 
root ganglia (DRG).  Sensitization of these neurons leads to hyperalgesia and 
allodynia, two common symptoms of chronic pain. 
The majority of these pronociceptive receptors and ion channels signal via 
phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis.  However, it is currently 
unknown which lipid kinases generate PIP2 in DRG neurons and if these kinases 
regulate pronociceptive receptor signaling.  The aim of this dissertation is to fully 
characterize the regulatory role of the predominant PIP2-synthesizing enzyme in 
  
iv 
nociceptive signaling and sensitization using a combination of genetic and 
pharmacological approaches. 
Our studies reveal that lipid kinase (LK) is expressed at the highest levels in 
DRG and, based on experiments with LK+/- mice, generates at least half of all PIP2 in 
DRG neurons.  Moreover, LK haploinsufficiency reduced pronociceptive receptor 
signaling and ion channel-mediated neuronal excitability in DRG neurons and 
reduced noxious thermal and mechanical sensitization in mouse models of chronic 
pain via PIP2-dependent mechanism(s).  In parallel, we developed a high-throughput 
screening assay to identify the first reported small molecule inhibitor of LK, 
UNC1.  UNC1 lowered PIP2 levels in DRG neurons, reduced pronociceptive receptor 
signaling, and attenuated noxious thermal and mechanical sensitization when 
administered intrathecally.  Collectively, this work demonstrates that LK regulates 
PIP2-dependent nociceptive signaling and sensitization and validates LK as a novel 
therapeutic target for chronic pain. 
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CHAPTER I 
INTRODUCTION 
 
Chronic pain and current therapeutics 
Chronic pain affects approximately 100 million American adults, making it 
more prevalent than diabetes, cancer, and heart disease combined1.  In addition 
to being in a perpetual state of discomfort, patients suffering from chronic pain 
are also plagued by depression, loss of sleep, and an inability to complete daily 
tasks, all of which lead to a significant decrease in overall quality of life1.  
Unfortunately, non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, 
and opioid-based analgesics such as morphine—the current first-line 
therapeutics for pain—have harmful side effects while only providing partial 
relief2.  The complexity of nociception (detection of noxious stimuli) and 
subsequent pain processing, ultimately resulting in cognitive awareness, creates 
many challenges for analgesic drug discovery and contributes to the 
ineffectiveness and adverse effects associated with current therapeutics3.  
Current therapeutic inadequacies highlight the need to identify novel molecular 
targets for analgesic drug development.  In order to identify novel therapeutic 
targets, mechanisms of peripheral nociceptive signaling and sensitization need to 
be further elucidated4. 
 2 
Nociceptive circuitry and peripheral sensitization 
Nociception is the detection and transduction of noxious stimuli by the 
peripheral and central nervous system, independent of cognitive awareness.  In 
contrast, pain is associated with perception and requires cognitive awareness and 
intact cortical and subcortical processing5.  Nociception is mediated by neurons 
(commonly referred to as nociceptors) whose cell bodies are located in dorsal root 
ganglia (DRG) (Figure 1.1).  These nociceptors have a bifurcated axon that extends 
into the target tissue (organs, skin, muscle, etc.) via a peripheral terminal and onto 
second order neurons in the spinal cord (primarily lamina I and II) via a central 
terminal3, 4, 6 (Figure 1.1).  Nociceptive neurons are responsible for the detection of 
noxious thermal, mechanical, and chemical stimuli and can be divided into two 
groups.  The first group consists of medium diameter neurons whose afferents are 
myelinated.  These afferents, referred to as Aδ fibers, are responsible for “fast” or 
“first” pain6.  The second group is composed of small diameter neurons whose 
afferents are not myelinated.  These unmyelinated afferents, referred to as C fibers, 
are responsible for the transduction of “slow” or “second” pain6.   
The second group, the C fiber nociceptors, is further differentiated into two 
subgroups, peptidergic and nonpeptidergic neurons4, 6 (Figure 1.1).  Peptidergic and 
nonpeptidergic neurons differ in their molecular composition, anatomical projections, 
and contribution to different pain modalities.  Peptidergic neurons express 
neuropeptides such as substance P and calcitonin gene-related peptide (CGRP) and 
their central termini project into the outer lamina (I and outer II) of the spinal dorsal 
horn7-9.  In contrast, nonpeptidergic neurons express prostatic acid phosphatase, 
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bind the plant isolectin B4 (IB4), and project their central termini into lamina II of the 
spinal cord7-9.  Importantly, peptidergic neurons primarily mediate detection of 
noxious thermal stimuli whereas nonpeptidergic neurons primarily mediate detection 
of noxious mechanical stimuli7-9 (Figure 1.1).  These molecular and anatomical 
distinctions are commonly used for differentiating various nociceptive signaling 
mechanisms in vivo and in vitro. 
Under normal physiological conditions, nociceptors function as a defense 
mechanism to protect against dangerous stimuli and promote avoidance of 
situations that evoke pain10.  This type of pain is called nociceptive or physiological 
pain3, 10, 11.  In contrast, persistent or chronic pain results when nociceptors become 
sensitized (Figure 1.2B)12.  Sensitization is characterized by a reduction in detection 
threshold and an increase in response to noxious stimuli which mediates two 
common symptoms of pain in humans, allodynia in which typically innocuous stimuli 
become painful and hyperalgesia in which a painful stimulus becomes more painful, 
respectively6, 10, 12.  Sensitization of nociceptors occurs most commonly after 
inflammation and nerve injury6, 10 giving rise to the two most common forms of 
chronic pain in humans, inflammatory and neuropathic pain, respectively2, 12.  It is 
important to note that central sensitization takes place primarily at the level of the 
spinal cord in nociceptor transmission neurons in the dorsal horn while peripheral 
sensitization occurs in neurons of the DRG12.  Central sensitization is dependent 
upon activity from the central terminal of the DRG (synaptic transfer from the 
nociceptor terminal to dorsal horn neurons) and is often preceded by peripheral 
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sensitization12.  The focus of this dissertation is on mechanisms that mediate 
peripheral sensitization in DRG neurons. 
 
G-protein-coupled receptor and ion channel mediated nociceptive signaling 
and sensitization 
Nociceptive, neuropathic, and inflammatory pain are mediated by several 
different molecular mechanisms; some of these mechanisms are unique to one type 
of pain while others are involved in multiple pain modalities13.  Transient receptor 
potential (TRP) channels are responsible for the detection of noxious thermal, 
mechanical, and chemical stimuli and are the predominant mediators of nociceptive 
pain.  Of particular interest to this dissertation is the non-selective cation channel, 
transient receptor potential vanilloid type I (TRPV1), as it is the predominant detector 
of noxious heat and is regulated by PIP214-17 (Figure 1.2A).  Furthermore, TRPV1 
detection of noxious heat is commonly used in rodents as a model of nociceptive 
pain due to the ease of the corresponding assay and will be used as such for this 
dissertation.  In addition, TRPV1 activation also contributes to the changes in 
nociceptor excitability that mediate persistent pain (Figure 1.2A). 
Although TRPV1 is the main regulator of thermal acute nociceptive pain, 
GPCRs are the more predominant mediators of nociceptive sensitization and 
persistent pain (Figure 1.2B).  It is well-established that nerve injury and 
inflammation result in the release multiple pronociceptive molecules, including 
bradykinin (BK), LPA, adenosine triphosphate (ATP) and prostaglandins3.  These 
ligands signal through a diverse set of Gq and Gs-coupled GPCRs 
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nociceptors18, 19.  Activation of Gq-coupled GPCRs via canonical Gq-coupling results 
in phospholipase C (PLC)-catalyzed hydrolysis of phosphatidylinositol 4,5 
bisphosphate (PIP2) to produce diacylglycerol (DAG) and inositol 1,4,5-triphosphate 
(IP3).  DAG activates protein kinase Cs (PKCs) that subsequently activates the 
mitogen-activated protein kinase (MAPK) cascade.  IP3 binds to IP3 receptors on the 
endoplasmic reticulum (ER), which results in an increase in cytoplasmic calcium 
from intracellular calcium stores.  In addition, Gs-coupled GPCRs can contribute to 
this pathway by exchange protein activated by cAMP (EPAC) activation of PLC20.  
Activation these downstream effectors results in nociceptor sensitization (Figure 
1.2B).  Importantly, GPCR activation and subsequent downstream effector activation 
can potentiate the activity of a variety of ion channels and modulate the 
hyperexcitability of the nociceptors following nerve injury and inflammation (Figure 
1.2B).  As mentioned above, sensitization of nociceptors through activation of 
GPCRs is one of the predominant underlying mechanisms for neuropathic and 
inflammatory pain13 (Figure 1.2B). 
In addition to the previously mentioned TRP channels, a variety of ion 
channels are responsible for regulating neuronal excitability—and more importantly 
hyperexcitability following nerve injury and inflammation—via mechanisms that are 
both independent of and dependent upon modulation by GPCRs21, 22.  Furthermore, 
an increase in excitability is crucial for prolonged nociceptive sensitization and 
persistent pain3, 6, 22.  Many different classes of ion channels regulate neuronal 
excitability including sodium, potassium, calcium and hyperpolarization channels3, 6, 
23-25.  Although a review of the distinct function of each of these ion channels is 
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beyond the scope of this dissertation, it is important to note that many of these ion 
channels depend on PIP2 for activity22, 24-26 (Figure 1.2B).   
Indeed, one important commonality between GPCR- and ion-channel 
mediated nociceptive signaling and sensitization is their dependence upon the lipid 
second messenger, PIP2 (Figure 1.2A and B).  PIP2 regulates TRPV1, a 
predominant mediator of nociceptive pain, as well as other ion channels responsible 
for the regulation of neuronal excitability.  Moreover, as discussed above, PIP2 is a 
crucial component of the Gq-coupled GPCR signaling pathway, which mediates 
nociceptive sensitization following nerve injury and inflammation.  Thus, PIP2 
represents a critical convergence point for many pain promoting pathways.  
 
Phosphatidylinositol 4,5-bisphosphate (PIP2) 
 Although PIP2 is only a minor constituent (<1%) of the plasma membrane, it is 
very important to a multitude of cellular processes and serves as prerequisite to 
other regulatory lipids in the phosphatidylinositol (PI) synthetic cascade27, 28 (Figure 
1.3).  As discussed above, PIP2 hydrolysis regulates both GPCR- and ion channel-
mediated signaling.  As outlined previously, PLC hydrolysis of PIP2 into DAG and IP3 
is crucial to GPCR signaling via a large number of downstream effectors including 
MAPKs and PKC.  In addition, PIP2 directly regulates channel activity of TRP 
channels and other ion channels via interactions with polybasic amino acids on the 
C terminus25.  However, the regulation of nociceptive signaling and sensitization by 
PIP2 most likely extends well beyond PIP2 hydrolysis.  Here, several additional PIP2 
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interactions that are pertinent to signaling in nociceptive DRG neurons will be 
discussed briefly.  
 PIP2 is critical for cytoskeletal dynamics via its interactions with both actin and 
tubulin.  PIP2 has an important regulatory interaction with tubulin, the main 
constituent of cytoskeletal microtubules.  Tubulin is responsible for the direct transfer 
of GTP to Gαq to initiate PLC activation and subsequent PIP2 hydrolysis29-31.  
Importantly, high concentrations of tubulin inhibit PLC-mediated signaling via PIP2 
interactions29, 32.  Moreover, intact microtubules contribute to TRPV1 stability and 
functionality33.   
PIP2 also interacts with actin and modulates actin dynamics through three 
distinct pathways: binding actin-capping proteins such as vinculin, serving as a 
scaffold for adaptor proteins such as adaptor protein 2 (AP-2), and regulating activity 
of Rho GTPases27.  Furthermore, actin dynamics play a critical role in GPCR 
signaling and may contribute to GPCR-mediation of chronic nociceptive 
sensitization34, 35.  For example, LPA receptor activation and subsequent calcium 
release plays an important role in the initiation of neuropathic pain16, 17, 39.  Actin 
rearrangements that occur following LPA receptor activation are required for LPA-
mediated calcium release (via LPA1 which also mediates LPA-induced neuropathic 
pain) 36-39.  Furthermore, prostaglandin-mediated nociceptive sensitization (via Gq 
activation of protein kinase C) requires an intact actin cytoskeleton to produce full 
inflammatory pain responses40.  Thus, PIP2-actin and PIP2-tubulin interactions 
provide other potential mechanisms for attenuation of nociceptive signaling via 
decreases in PIP2. 
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Many of these processes are dependent upon adequate PIP2 synthesis via 
phosphatidylinositol kinases.  Type 1 phosphatidylinositol 4-phosphate 5-kinases 
(PIP5K1s) and type 2 phosphatidylinositol 5-phosphate 4-kinases (PIP4K2s) 
synthesize PI(4,5)P2 by phosphorylating phosphatidylinositol 4-phosphate, [PI(4)P] 
and phosphatidylinositol 5-phosphate [PI(5)P], respectively (Figure 1.3).  PI(4)P is 
the most abundant monophosphoinositide and is present at 10-fold greater 
concentrations than PI(5)P, suggesting that PIP5K1s are the predominant PIP2 
synthesizing enzymes.  It must be noted that PIP5K1s can also phosphorylate 
phosphatidylinositol 3-phosphate, PI(3)P to form PI(3,5)P2; however, it has been 
shown that PIP5K1 generation of PI(4,5)P2 is the major regulatory mechanism for 
GPCRs and ion channels 25, 27, 41 (Figure 1.3).   
 
Type 1 Phosphatidylinositol 4-phosphate 5-kinases (PIP5K1s)  
There are three mammalian Pip5k1 genes, Pip5k1a, Pip5k1b, and Pip5k1c, 
that express three PIP5K1 isozymes:  PIP5K1A, PIP5K1B, and PIP5K1C (Figure 
1.4).  Due to patentability of portions of this work, PIP5K1C was previously referred 
to as lipid kinase (LK) in the abstract.  The three isozymes are >80% identical at the 
amino acid level within the kinase catalytic domain.  However, they have very little 
sequence homology within their N and C termini; these isozyme-specific regions 
allow differentiated functions of each isoform within cells42, 43 (Figure 1.4).  Each 
isoform has differential expression within cells and across murine tissues.  It must be 
noted that human PIP5K1A is homologous to murine PIP5K1B and human PIP5K1B 
is homologous to murine PIP5K1A (Figure 1.4).  PIP5K1A is ubiquitously expressed 
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in murine tissue, is primarily expressed in the nucleus, and translocates to the 
membrane following receptor activation42-44.  PIP5K1B is also ubiquitously 
expressed in murine tissue but is located in the perinuclear region44.  Unlike 
PIP5K1A and PIP5K1B, PIP5K1C is not ubiquitously expressed and is instead 
expressed predominantly in neuronal tissue (with minimal expression in the lung and 
kidney).  PIP5K1C localizes to the cytoplasm, plasma membrane, and intracellular 
membranes41, 45, 46.  
 Characterization of PIP5K1A and PIP5K1B has been carried out utilizing a 
variety of cell types and roles in membrane ruffling, endocytosis, and actin dynamics 
have all been elucidated47, 48.  It is common for PIP5K1A and PIP5K1B to have 
overlapping functions; however, like the specialized expression profile of PIP5K1C, it 
is rare that PIP5K1C shares common functionality with PIP5K1A and PIP5K1B47, 48.  
Endocytosis is the one function in which all three isozymes play a role; however, it is 
suggested that PIP5K1C has a specialized role in interacting with AP-2 in this 
process48, 49.  Furthermore, in bone marrow macrophages, PIP5K1A and PIP5K1C 
have very distinct functions that mediate different steps in phagocytosis47, 48.  The 
role of PIP5K1C has primarily been studied in cortical synaptic transmission45, 
GPCR-mediated signaling41, regulation of focal adhesions50, and AP-2 mediated 
endocytosis49.  Moreover, the functions of PIP5K1C can be further differentiated by 
the involvement of the two different splice isoforms, PIP5K1C635 and PIP5K1C661.  
Importantly, PIP5K1C635 is the primary splice variant responsible for the regulation 
of GPCR-mediated signaling whereas PIP5K1C661 is the primary splice variant 
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responsible for the interactions with talin and AP-2 which mediate endocytosis and 
focal adhesions41, 48-50 (Figure 1.4).  
Although the expression profile and functionality of PIP5K1s in DRG has yet 
to be determined, previous data suggest that PIP5K1C is the predominantly 
expressed isoform given its specialized expression in neuronal tissue.  Pip5k1c 
homozygous mice (Pip5k1c-/-) exhibit a perinatal lethal phenotype (death within 24 
hours of birth), presumably due to lack of mobility and an inability to feed45, 51.  
Heterozygous mice (Pip5k1c+/-) live to adulthood and reproduce normally.  
Previously characterized phenotypes in Pip5k1c-/- embryos include reduced synaptic 
transmission and impairment of clathrin-mediated endocytosis in cortical neurons 
and phagocytosis defects in bone marrow macrophages45, 47.  In addition, calcium 
signaling in cochlear nonsensory cells hearing at high frequencies (> 20 kHz) is 
reduced in adult Pip5k1c+/- mice 52.   
 
Summary and Significance 
Therapeutic inadequacies and harmful side effects of current analgesics 
highlight the need to better understand the underlying signaling mechanisms of 
maladaptive pain pathology that would promote the identification of novel therapeutic 
targets and treatments.  Structural features that are likely to interact with drug-like 
compounds determine the druggability of a potential therapeutic target53.  The affinity 
of drug-like compounds to block the catalytic site of a kinase, which precisely 
abolishes the kinase’s biological activity, makes kinases particularly attractive 
therapeutic targets53, 54.  Discovery and characterization of novel regulatory kinases 
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that mediate peripheral sensitization offers the potential to develop new analgesics 
that are likely to improve efficacy.  In addition, characterization of kinases that are 
primarily expressed in nociceptors will provide potential for mitigating unwanted side 
effects that plague current therapeutics.    
Given that PIP5K1C, a potentially druggable kinase, is enriched in neuronal 
tissue and accumulating evidence indicates that many pronociceptive signaling 
mechanisms depend on PIP2, we hypothesize that PIP5K1C regulates PIP2-
dependent proniceptive signaling in DRG neurons.  Furthermore, we hypothesize 
that reductions in PIP5K1C will reduce nociceptive sensitization via PIP2-dependent 
mechanisms.  The aim of this work is to rigorously characterize the role of PIP5K1C 
in nociceptive signaling in vitro and sensitization in vivo.  We seek to accomplish this 
aim using genetic deletion of Pip5k1c in mice (Aim 1 and 2) and pharmacological 
inhibition of PIP5K1C (Aim 3). 
Completion of this work will improve our understanding of signaling 
mechanisms that mediate nociceptive sensitization, highlight lipid kinases as novel 
regulators of pronociceptive signaling, and provide insights into potential therapeutic 
treatments for chronic pain.   
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Specific Aims 
1) Utilize Pip5k1c genetic knockout mice to investigate the regulatory role of 
PIP5K1C in nociceptive signaling and sensitization 
Central Hypothesis:  Genetic deletion of Pip5k1c will attenuate PIP2-dependent 
nociceptive signaling and sensitization. 
Specific Hypotheses: 
a) Genetic deletion of Pip5k1c will reduce PIP2-dependent GPCR- and ion 
channel-mediated pronociceptive receptor signaling in DRG neurons 
b) Genetic deletion of Pip5k1c will reduce acute GPCR-mediated nocifensive 
behaviors and ion channel-mediated thermal sensitivity  
c) Genetic deletion of Pip5k1c will attenuate PIP2-dependent nociceptive 
sensitization in mouse models of chronic pain 
2) Characterize a sensory-neuron specific Pip5k1c knockout mouse to determine 
phenotypic site of action. 
Central Hypothesis:  Genetic deletion of Pip5k1c in sensory neurons only will 
reduce nociceptive signaling and sensitization similar to or greater than 
reductions observed in global heterozygotes. 
Specific Hypotheses:  
a) Sensory neuron-specific deletion of Pip5k1c will reduce PIP2-dependent 
nociceptive signaling in DRG neurons 
b) Sensory neuron-specific deletion of Pip5k1c will attenuate PIP2-dependent 
nociceptive sensitization in mouse models of chronic pain 
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3) Develop a high-throughput screening assay to identify potent inhibitors of 
PIP5K1C that will be used to validate PIP5K1C as a novel therapeutic target. 
Central Hypothesis:  Development of a high-throughput screening assay will 
identify inhibitors (or promising scaffolds for medicinal chemistry optimization) of 
PIP5K1C that can be used to evaluate pharmacological inhibition of PIP5K1C in 
nociceptive signaling and sensitization. 
Specific Hypotheses:  
a) Development of a high-throughput screening assay will identify inhibitors 
of PIP5K1C 
b) If identified, potent inhibitors will reduce nociceptive signaling in DRG 
neurons 
c) If identified, potent inhibitors will have antinociceptive effects when 
administered intrathecally. 	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Figures 	  
 
Figure 1.1.  Schematic of peripheral nociceptive circuitry. 
Dorsal root ganglion (DRG) neurons extend a bifurcated axon into the target tissue 
(such as the skin) and into the dorsal horn of the spinal cord to detect and process 
painful stimuli.  Pain-sensing neuron in the DRG can be divided into two subgroups, 
peptidergic neurons that express calcitonin gene related peptide (CGRP) and mainly 
detect noxious thermal/heat stimuli and nonpeptidergic neurons that bind isolectin 
B4 (IB4) and primarily detect mechanical painful stimuli.  This figure has been 
modified from Zylka et al., 20058. 
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Figure 1.2.  DRG-mediated nociceptive signaling in the three types of pain. 
(A) TRPV1-mediated signaling in nociceptive (acute, defense mechanism) pain.  
TRPV1 signaling is dependent on PIP2.  (B) GPCR-mediated nociceptive signaling 
that leads to sensitization of nociceptors within the DRG.  Nociceptive sensitization 
is dependent on PIP2-sensitive GPCRs and ion channels that mediate 
hyperexcitability following nerve injury and inflammation. 
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Figure 1.3.  Phosphatidylinositol (PI) synthetic pathways. 
PIP2 is primarily synthesized from PI(4)P by type I PIP5K (blue).  Kinases involved in 
the synthesis of all other phosphoinositides are shown.  R2 and R1 are the fatty acid 
chains that make up diacylglycerol (DAG).  Phosphate groups are red. 
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Figure 1.4.  Type I PIP5Ks. 
The three murine and human PIP5K1s have a highly conserved kinase core domain 
(blue).  Isozyme-specific regions at the N and C termini of each protein allow for 
differentiated functionality within cells.  PIP5K1C668/661 has a C terminal tail that is 
specialized in binding two cytoskeletal proteins, talin and adaptor protein-2 (AP-2). 
 
  
CHAPTER II 
 
PIP5K1C REGULATES PRONOCICEPTIVE SIGNALING IN VITRO AND 
NOCICEPTIVE SENSITIZAITON IN VIVO 
 
Introduction 
Tissue inflammation and nerve injury result in the release of a complex set of 
molecules that sensitize DRG neurons and contribute to chronic pain6.  These 
molecules activate molecularly diverse pronociceptive receptors and ion channels 
found on the membrane of DRG neurons.  While these receptors represent attractive 
targets for analgesic drug development, efforts to block individual pronociceptive 
receptors have so far failed to produce effective treatments for chronic pain3.  This 
likely reflects the fact that multiple pronociceptive receptors and ion channels are 
activated during initiation and maintenance of chronic pain.   
One approach to treat chronic pain that eliminates the issue of receptor 
diversity is to target points where different signaling pathways converge.  Indeed, 
drugs that block signaling proteins that are several steps downstream from receptor 
activation, including protein kinase Cε (PKCε) and mitogen activated protein kinases 
(MAPKs), reduce nociceptive neuron sensitization, thermal hyperalgesia, and 
mechanical allodynia in animal models55-58.  Unfortunately, drugs that inhibit MAPKs 
or PKCε have shown modest to no efficacy in treating chronic pain in humans55, 59-61.  
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Ineffectiveness of these inhibitors has been attributed to several issues including trial 
design, subtherapeutic dosing, and inability to confirm inhibitor engagement with the 
target proteins. 
Another convergence point, albeit one that has not been fully explored in the 
context of treating pain, is immediately downstream of multiple pronociceptive 
receptors and ion channels.  Many pronociceptive receptors, including Gq-coupled 
receptors, Gs-coupled receptors (via EPAC), and receptor tyrosine kinases, initiate 
signaling upon phospholipase C (PLC)-catalyzed hydrolysis of the lipid second 
messenger PIP23, 6.  PIP2 hydrolysis produces diacylglycerol (DAG) and inositol-
1,4,5-trisphosphate (IP3), which regulate nociceptive sensitization via multiple 
pathways, including PKC-dependent modulation of ion channels, MAPK activation, 
and IP3-mediated calcium influx3, 23, 62.  In addition, many ion channels that detect 
noxious heat and regulate neuronal excitability are dependent upon PIP2 for 
activity23, 25, 63.  Thus, PIP2 is a convergence point for diverse receptors, ion 
channels, and signaling pathways that promote and maintain nociceptive 
sensitization.  In turn, this suggests it may be possible to reduce signaling through 
pronociceptive receptors and ion channels and reduce pain sensitization by 
inhibiting the lipid kinase(s) that generate(s) the majority of PIP2 in DRG neurons.   
Type 1 phosphatidylinositol 4-phosphate 5-kinases (Pip5k1s) generate PIP2 
by phosphorylating the 5 position on the inositol ring of phosphatidylinositol 4-
phosphate [PI(4)P].  There are three mammalian Pip5k1 genes (Pip5k1a, Pip5k1b 
and Pip5k1c)64.  Of these, Pip5k1c is highly expressed in the brain46.  PIP5K1C 
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regulates receptor-mediated calcium signaling, actin cytoskeletal dynamics, 
endocytosis, and exocytosis41, 46, 51, 65-67.   
Previous studies examined the functions of Pip5k1c in the brain with knockout 
mice45, 51, 52, 68.  Homozygous knockout mice (Pip5k1c-/-) have ~50% less PIP2 in 
their brain and die within 24 hours of birth due to impaired mobility and an inability to 
feed45, 68.  These data suggest a critical role for PIP5K1C in generating PIP2 in 
neurons and in nervous system development.  In contrast, heterozygous (Pip5k1c+/-) 
mice are viable, reproduce normally, have normal levels of PIP2 in the brain and 
showed no phenotypes in an extensive battery of tests, including multiple tests of 
neurological function45, 68.  The only phenotype observed thus far in Pip5k1c+/- mice 
is high-frequency (>20 kHz) hearing loss, a phenotype ascribed to Pip5k1c 
haploinsufficiency in non-sensory cells of the auditory system52.   
Prior to completion of these studies, it was unknown which enzymes 
generated PIP2 in nociceptive DRG neurons or if these enzymes regulated 
nociception in vitro or in vivo.  Herein, we report that PIP5K1C is expressed in the 
majority of all DRG neurons, generates at least half of all PIP2 in the DRG and 
regulates nociceptive sensitization in response to diverse stimuli that cause pain.  
 
Methods 
Animals 
All procedures involving vertebrate animals were approved by the Institutional 
Animal Care and Use Committee at the University of North Carolina at Chapel Hill.  
Pip5k1c+/- mice were provided by Pietro de Camilli at Yale University (also available 
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from The Jackson Laboratory, #008515)45.  Mice were genotyped using PCR on 
extracted tail DNA and the following primers: Neo4R, 5’−CAC CCC TTC CCA GCC 
TCT GA−3’, PIPKRV1, 5’−CCT CAC ATC CTG CTC ACT CAG GAC C−3’, and 
PKWT1, 5’−GCC TCA CAG AGA TTT GAC GTG TCA G−3’.  Pip5k1c+/- mice were 
identified by the presence of a 650 bp knockout band (Neo4R and PIPKRV1) and a 
250 bp WT band (PKWT1 and PIPKRV1).  All mice were backcrossed to C57BL/6 
mice for at least 10 generations. 
 
In situ hybridization 
Mice were sacrificed using pentobarbital.  Lumbar DRG were dissected from 
adult (6-8 weeks) male WT mice.  Gene-specific probe preparation and in situ 
hybridization were completed as previously described69.  Briefly, tissue was mounted 
in TissueTek immediately following dissection and cryosectioned at 20 µm.  Non-
isotopic in situ hybridization was performed using digoxigenin-labeled cRNA probes 
for each of the three isoforms and standard nitro blue tetrazolium (NBT) and 5-
bromo-4-chloro-3-indolyl phosphate (BCIP) stain.  Double fluorescence in situ 
hybridization was performed by the UNC in situ hybridization core using previously 
described methods70. 
 
Immunohistochemistry 
Mice were sacrificed using pentobarbital.  Lumbar DRG and spinal cord were 
dissected from adult (6-8 week old) male mice and prepared as described previously 
71, 72.  Briefly, tissues were immersion-fixed in 4% paraformaldehyde for 4 hours and 
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cryopreserved in 30% sucrose at 4°C for 3 days.  Tissue was embedded in 
TissueTek and cryosectioned at 20 µm.  Sections were immunostained thaw 
mounted onto SuperFrost Plus slides.  The following primary antibodies were used 
for overnight incubations (at 4°C): sheep anti-CGRP (1:200; Enzo Life Sciences, 
CA1137), mouse anti-NeuN (1:250; Millipore, MAB377), and rabbit anti-PIP5K1C 
(1:200, generously provided by Hiroyuki Sakagami).  Fluorescently conjugated 
secondary antibodies were purchased from Invitrogen and were used at 1:200 for for 
2 hours at room temperature.  Alexa-conjugated Isolectin IB4 (1:1000; Invitrogen) 
was added to the secondary antibody incubation.  All staining soltuons were made in 
Tris-buffered saline containing Triton (0.05 M Tris, 2.7% NaCl, 0.3% Triton-X 100, 
pH 7.6).  All images were obtained using a confocal microscope (Zeiss LSM 510). 
 
Immunocytochemistry 
Biotinylated PIP2 primary antibody was purchased from Echelon Biosciences 
(Z-B045) and used according to the manufacturer’s instructions.  All PIP2 staining 
was completed at 37°C with Tris-buffered saline (50 mM Tris and 150 mM NaCl at 
pH 7.4).  Chicken anti-NeuN (1:250; Aves) was added to the primary incubation.  
Alexa-conjugated streptavidin (1:2000; Invitrogen) and fluorescently labeled anti-
chicken antibodies (1:1000;Invitrogen) were used for secondary detection.  For 
evaluation of cytoskeletal dynamics, rabbit anti beta III tubulin (1:500, Abcam), and 
mouse anti-NeuN (1:250, Millipore) primary antibodies were used overnight at 4°C.  
Fluorescently conjugated secondary antibodies and fluorescently conjugated 
phalloidin were used at 1:1000 for 2 hours at room temperature.  All solutions for 
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cytoskeletal staining were made in phosphate buffered saline (PBS) containing 0.3% 
Triton, 3% BSA, and 0.1% sodium azide.  Additionally 10% normal goat serum was 
added to the primary antibody solution.  All images were obtained using a Leica 
TCS-SL confocal microscope.   
 
Western blot analysis 
Following decapitation, lumbar DRG (L3-L5, bilateral), lumbar spinal cord, 
and brain (frontal cortex) were dissected from adult male mice (6-8 weeks old) and 
embryos (E17.5-18.5).  Tissue lysates were prepared in radioimmunoprecipitation 
buffer (RIPA) buffer (50 mM Tris, 1% Triton X-100, 0.25% sodium deoxycholate, 
0.1% sodium dodecyl sulfate, 1 mM ethylenediaminetetraacetic acid and 150 mM 
sodium chloride) containing protease inhibitors (Roche Complete Mini Tablets, 
11836153001 and 1 mM phenylmethylsulfonyl fluoride) and separated by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).  Gels were 
transferred onto polyvinylidene fluoride (PVDF) membranes and blocked with 5% dry 
milk (BioRad).  Primary antibodies were prepared in Tris buffered saline with Triton 
(100 mM Tris, 165 mM sodium chloride, and 0.1% Tween 20) containing 5% BSA.  
PIP5K1C antibody (1:500) was a generous gift from P. De Camilli.  Anti-β-actin 
(1:3000; Abcam) served as a loading control.  Secondary antibodies (1:10,000; Li-
Cor IRDye 680 and 800) were prepared in TBS-T containing 5% dry milk.   
 
ELISA PIP2 quantification 
PI(4,5)P2 mass enzyme-linked immunosorbent assay (ELISA) was purchased 
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from Echelon Biosciences (K-4500) and performed according to the manufacturer’s 
instructions with the following alterations.  Lumbar DRG (L3-L5, bilateral), lumbar 
spinal cord and cerebral cortex were dissected from adult male mice (6-8 weeks old) 
and frozen immediately on dry ice.  All DRG were dissected from embryos (E17.5-
18.5) and frozen immediately on dry ice.  Tissue was homogenized and sonicated 
prior to lipid extraction.  DRG samples were diluted 1:40 and spinal cord and brain 
samples were diluted 1:200 prior to use in the ELISA assay.  Bicinchoninic acid 
(BCA) protein determination assay (ThermoScientific, 23225) was completed for 
each sample following the manufacturer’s instructions.  Protein content for each 
sample was used for normalization. 
 
Neuron culture 
All DRG were dissected from 3-8 week old male mice following decapitation.  
Neurons were dissociated with manual trituration using a fire polished Pasteur 
pipette in a solution of 2 mg/mL collagenase (Worthington, CLS1) and 5 mg/mL 
dispase (Gibco, 17105-041).  Neurons were cultured with Neurobasal A medium 
(Gibco, 10888) supplemented with 2% B27 (Gibco, 17504), 2 mM L-glutamine 
(Gibco, 25030), 1% penicillin/streptomycin (Gibco, 15140), 50 ng/mL glial derived 
neurotrophic factor (GDNF; Millipore, GF030) and 25 ng/mL nerve growth factor 
(NGF; Millipore, 01-125) in the absence of serum. Neurons were plated onto 
coverslips coated with 1 mg/mL poly-D-lysine (Sigma, P7886) and 10 µg/mL laminin 
(Sigma, L2020) and cultured for 18-24 hours prior to use. 
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Calcium imaging 
Calcium imaging of dissociated neurons was completed as described 
previously using Fura 2-acetoxymethyl ester (2 µM; F1221, Invitrogen)73.  Briefly, 
neurons were incubated with 2 µM Fura 2-AM for 60’ followed by 30’ incubation with 
Hanks buffered saline solution (HBSS) prior to carrier/PIP2 incubation.  Neurons 
were then incubated with either carrier alone (2 µM; Echelon Biosciences, P-9C2) or 
carrier + PIP2 (2 µM; Echelon Biosciences, P-4516) for 15 minutes prior to imaging.  
Carrier and PIP2 complexes were formed by incubating together in HBSS at room 
temperature for 15 minutes prior to use.  LPA (10 µM; Avanti Polar Lipids, 857130), 
17-PT-PGE2 (10 µM; Cayman Chemical 14810), Capsaicin (1 µM; Sigma M2028) 
and KCl (100 mM; Fisher P330) were used for neuron stimulation. 
  
Electrophysiology 
Recordings in DRG neurons were carried out as previously described74.  
Briefly, small (15-20 µm), presumably nociceptive, DRG neurons were identified 
using an epiflourescence microscope (Nikon Eclipse FN1) equipped with IR-DIC 
optics, and visualized with a 40X water-immerzion objective (NIR Apo 40X/0.80W, 
Nikon).  DRG neurons were perfused at 2 mL/min with a bath solution that contained 
(in mM): 10 HEPES, 140 NaCl, 4 KCl, 2 MgCl2, 2 CaCl2, 5 glucose at pH 7.4, 300 
mOsm.  The electrode solution contained (in mM): 130 potassium gluconate, 5 NaCl, 
1 MgCl2, 1 EGTA, 10 HEPES, 4 NaATP, with pH adjusted to 7.3 with KOH, and an 
osmolarity of 295 mOsm.  For some experiments, PIP2-diC8 (10 µM) was added to 
the pipette solution.  Patch pipettes made from borosilicate glass were pulled to a tip 
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resistance of 3-6 MΩ with a Sutter P-2000 electrode puller.  Whole-cell, current 
clamp recordings were carried out using a Multiclamp 700B amplifier, and captured 
at 10kHz with an Axon Digidata 1440A and pClamp 10 software.  
Field recordings in transverse mouse spinal cord slices were carried out as 
previously described 75.  Mouse spinal cords were dissected and sliced (800-900 
µm) at 4°C in buffer that contained (in mM): 87 NaCl, 2.5 KCl, 1.25 NaH2PO4, 25 
NaHCO3, 0.5 CaCl2, 7 MgCl2, 75 sucrose, 10 glucose, 1.5 ascorbic acid.  The tissue 
was continuously bubbled with 95%O2/5%CO2.  Slices were incubated at 35°C for 
45 minutes in artificial cerebrospinal fluid (ACSF) that contained (in mM) 125 NaCl, 
2.5 KCl, 1.25 NaH2PO4, 26 NaHCO3, 2.5 CaCl2, 1.5 MgCl2, 25 glucose.  The slices 
were then transferred to the recording chamber and the dorsal root was suctioned 
into a glass electrode in order to stimulate all sensory afferents.  Field potential 
electrodes were pulled from borosilicate glass on a Sutter P-97 puller to a tip 
resistance of 1-2 MΩ.  The field electrode was placed in lamina II then the dorsal 
root was stimulated for 0.5 ms at 5x the intensity needed to evoke a maximal 
response.  The resulting signals were filtered at 1 kHz, amplified 1000 times, and 
captured at 10 kHz.  Stimulus strength was then increased (0.1 Hz, repeated five 
times at each stimulus strength).  To assess synaptic depletion and recovery, a 
maximal strength stimulus was presented to the slices at 10 Hz for 100 trials.  
Immediately after synaptic depletion stimulation, the slices were then stimulated at 
the same maximal stimulus strength, but at a frequency of 0.1 Hz for 15 minutes to 
measure fEPSP amplitude.     
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Rodent models of nociceptive and chronic pain 
This dissertation will use four rodent models of pain that have been designed 
to mimic human nociceptive, inflammatory, and neuropathic pain.  To investigate 
nociceptive pain (detection of noxious stimuli as a defense mechanism), we will use 
noxious heat (>43°C) applied to rodent’s hindpaw10, 72, 76.  To investigate 
inflammatory pain, we will use the complete Freund’s adjuvant (CFA) induced 
inflammatory pain model72.  Two neuropathic pain models will be used: the spared 
nerve injury (two branches of the sciatic nerve are severed) and Lysophosphatidic 
acid (LPA) chemically induced neuropathic pain model38, 39, 77, 78.  Radiant heating 
(Hargreaves method) will be used to assess thermal hyperalgesia and mechanical 
von Frey testing will be used to assess mechanical allodynia in the rodent models of 
chronic pain79, 80. 
 
Behavioral assays 
Pronociceptive ligands (4.1 µg LPA; 1.2 µg 17-PT-PGE2, in 0.9% saline) were 
injected into the left hindpaw and the amount of time spent licking was measured for 
5 minutes.  Thermal sensitivity was measured using a Plantar Test apparatus (IITC) 
to heat each hindpaw and the latency for hindpaw removal was recorded.  One 
measurement was taken for each hindpaw to determine the withdrawal latency in 
seconds.  The radiant heat source intensity was calibrated so that the average 
withdrawal latency for WT mice was ~10 s.  Cut off time was 20 s.  Mechanical 
sensitivity was measured using an electronic von Frey apparatus (IITC) and a semi-
flexible tip.  Three measurements for each hindpaw were taken and averaged to 
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determine the withdrawal threshold in grams.  Inflammatory (CFA) and neuropathic 
(LPA and spared nerve injury) models of chronic pain were performed as described 
previously71, 77, 78.  Intrathecal injections (5 µL) were performed in unanesthetized 
mice using the direct lumbar puncture method 81.  For the hot plate assay, the mice 
were restrained by scruffing and one hindpaw was placed on a metal surface of a 
given temperature (45°, 50°C, or 55°C).  The latency for the animal to remove or 
shake the hindpaw was recorded once per animal per temperature.  At least 30 
minutes elapsed between measuring each temperature.  Cut off was 20 seconds for 
all temperatures.  The cotton swab assay was used to measure innocuous 
mechanical sensitivity 82.  For rotarod testing, the animals were placed on a rotating 
rod and the latency to fall off was recorded.  Gait measurements were taken by 
painting the hindpaws with ink and allowing the mice to walk in a straight line down 
an enclosed runway.  Stride was measured as the distance (in cm) between the left 
hindpaws (5 measurements per animal were averaged).  Stance was measured as 
distance (in cm) between the left hindpaw and the subsequent step of the right 
hindpaw (5 measurements per animal were averaged).  For all behavioral assays, 
mice were habituated to the testing apparatus/method and experimenter for 3-5 days 
prior to performing the assay. 
 
Results 
PIP5K1C generates at least half of all PIP2 in DRG neurons 
To determine which Type 1 Pip5ks were expressed in the DRG, we 
performed in situ hybridization with probes for the three known mammalian Pip5k1 
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genes.  We found that Pip5k1c was expressed at higher levels in adult DRG than the 
other Pip5k1 genes and was present in nearly all DRG neurons (Figure 2.1A-2.1C).  
PIP5K1C is also present in the brain at higher levels than PIP5K1A and PIP5K1B46.  
Consistent with widespread expression in all DRG neurons, we found that Pip5k1c 
was expressed in virtually all peptidergic (96.7%; n=220 counted) and 
nonpeptidergic (96.1%; n=210 counted) nociceptive neurons, marked by calcitonin 
gene-related peptide-alpha (Cgrpa) and Prostatic acid phosphatase (Acpp), 
respectively (Figure 2.1D and 2.1E) 71, 72.  Using a recently developed antibody to 
the c1 isoform83, we found that PIP5K1C was present on the plasma membrane and 
intracellular membranes of most DRG neurons (Figure 2.1F and 2.1G). 
 We next tested the extent to which PIP5K1C generated PIP2 in DRG using 
Pip5k1c knockout mice and a competitive binding enzyme-linked immunosorbent 
assay (ELISA) for PIP2 45, 51, 84.  We quantified PIP5K1C protein and PIP2 levels in 
the DRG of wild-type (WT; Pip5k1c+/+), Pip5k1c+/-, and Pip5k1c-/- embryonic (E17.5-
E18.5) mice.  We found that PIP5K1C protein and PIP2 levels were reduced (by 
~50%) in the DRG of Pip5k1c+/- embryonic mice (Figure 2.2A-2.2C).  No PIP5K1C 
protein was detectable in DRG from Pip5k1c-/- embryonic mice, confirming complete 
gene deletion and antibody specificity (Figure 2.2A and 2.2B).  In addition, PIP2 was 
reduced by ~70% in DRG from Pip5k1c-/- embryonic mice (2.2C), suggesting 
PIP5K1C generates the majority of all PIP2 in DRG, at least in embryonic mice.   
Pip5k1c+/- mice live into adulthood and reproduce normally45.  Therefore, we 
quantified PIP5K1C protein and PIP2 levels in the DRG from Pip5k1c+/- adult mice 
and WT littermate controls.  PIP5K1C protein was reduced by ~40% and PIP2 levels 
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were reduced by ~50% in the DRG of adult Pip5k1c+/- mice (Figure 2.3A-2.3C).  In 
contrast, PIP2 was not significantly reduced in spinal cord or brain from adult 
Pip5k1c+/- mice (Figure 2.3C).  Likewise, others reported that PIP2 was not reduced 
in the brain of embryonic Pip5k1c+/- mice using a different quantification method45, 51.  
In addition, we used immunofluorescence staining to examine PIP2 levels at the 
membrane of cultured adult DRG neurons.  Quantification of the average perimeter 
(membrane) staining intensity in confocal images revealed that membrane PIP2 
levels were reduced by ~50% in small-to-medium diameter (≤ 27 µm) neurons of 
Pip5k1c+/- mice compared to WT controls (Figure 2.3C and 2.3D).  Taken together, 
our data indicate that PIP5K1C generates at least half of all PIP2 in the DRG, 
including small-to-medium diameter, presumably nociceptive, DRG neurons.  
Moreover, our data indicate that PIP2 is selectively reduced in DRG of Pip5k1c+/- 
adult mice, but is not reduced in other regions of the nervous system that processes 
pain and somatosensory stimuli, including spinal cord and brain. 
 
  Pip5k1c haploinsufficiency attenuates TRPV1-mediated calcium signaling 
Since PIP2 was reduced by 50% at the membrane of Pip5k1c+/- DRG 
neurons, we hypothesized that pronociceptive GPCRs and ion channels that require 
PIP2 for activity would signal less efficiently in DRG neurons of Pip5k1c+/- mice.  We 
began our signaling studies by focusing on TRPV1, the nonselective cation channel 
that mediates detection of noxious heat (“heat pain”) and is stimulated by capsaicin, 
the active ingredient in chili peppers76.  As mentioned previously, we use TRPV1-
mediated assays to investigate acute nociceptive pain in vivo using noxious thermal 
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assays; however, in vitro we use the potent agonist, capsaicin to study activity of the 
channel.  It is well known that PIP2 regulates TRPV1 signaling; although, the 
mechanism by which it regulates the channel is highly debated14-16, 63, 85.  
Regardless, we sought to determine the extent to which TRPV1 signaling was 
effected in Pip5k1c+/- neurons.  We monitored capsaicin-evoked calcium responses 
in small diameter (≤27 µm) DRG neurons using the ratiometric calcium (Ca2+) 
indicator dye, Fura 2-AM.  Potassium chloride (KCl) activates neuron-specific 
voltage-gated calcium channels and was used to distinguish neurons from other cell 
types in the culture and to assess cell health.  We observed a ~40% reduction in 
TRPV1-evoked calcium responses (quantified as area under the curve of the 
capsaicin-evoked response in each responding neuron) in Pip5k1c+/- neurons 
compared to WT neurons (Figure 2.4A and 2.4B).  Importantly, calcium responses 
were fully restored to WT levels when excess PIP2 was delivered to Pip5k1c+/- 
neurons prior to imaging; indicating signaling deficits in Pip5k1c+/- neurons are PIP2-
dependent (Figure 2.4A and 2.4B).  There were no deficits observed in KCl-evoked 
responses further supporting the notion that deficits in Pip5k1c+/- neurons are due to 
PIP2 reductions and not due to poor cell health (Figure 2.4A and 24B).  Collectively, 
these data show that TRPV1-mediated signaling in Pip5k1c+/- DRG neurons is 
blunted via a PIP2-dependent mechanism and led us to hypothesize that TRPV1-
mediated detection of noxious heat in vivo may also be reduced in Pip5k1c+/- mice. 
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Pip5k1c haploinsufficiency reduces acute thermal sensitivity presumably 
mediated by TRPV1 
To test this hypothesis, we evaluated withdrawal latencies of the hindpaw in 
Pip5k1c+/- and WT mice at noxious temperatures that require TRPV1 for detection 
(>43°C) in our model of acute nociceptive pain.  Pip5k1c+/- mice had significantly 
increased withdrawal latencies compared to WT mice at all three noxious 
temperatures tested, 45°, 50°, and 55°C (Figure 2.4C).  These data suggest that 
TRPV1 functions less efficiently in vivo, at least when detecting noxious heat.  
However, when capsaicin (2 µg) was injected into the hindpaw of Pip5k1c+/- and WT 
mice and nocifensive licking was monitored for 5 minute following injection, there 
was no difference in time spent licking between Pip5k1γ+/- and WT mice (data not 
shown).  Differing mechanisms of noxious heat activation of TRPV1 and agonist 
activation (capsaicin) of TRPV1 may explain the discrepancies observed in the in 
vivo thermal assay and nocifensive licking assay86.  Additional testing at various 
concentrations of capsaicin (to obtain dose-response relationships) may be 
beneficial in evaluating differences in WT and Pip5k1c+/- mice.  Collectively, these 
data suggest that TRPV1-mediated detection of noxious heat is blunted in Pip5k1c+/- 
mice; however, the extent to which capsaicin-induced acute nociceptive pain is 
altered is less clear and requires further investigation.   
 
Pip5k1c haploinsufficiency attenuates pronociceptive GPCR signaling 
Nerve injury and inflammation release a complex set of molecules that 
activate GPCRs and lead to sensitization of DRG neurons.  These GPCRs are 
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dependent on PIP2 for activity.  Since PIP2 levels in the membrane were reduced by 
~50% in DRG neurons, we hypothesized that pronociceptive GPCRs that couple to 
phospholipases and PIP2 hydrolysis would signal less effectively in Pip5k1c+/- mice.  
To test this hypothesis we used the same calcium-imaging assay described above to 
quantify lysophosphatidic acid (LPA) and 17-phenyl trinor prostaglandin E2 (17-PT 
PGE2) evoked calcium responses in small diameter DRG neurons.  LPA evokes 
Ca2+ influx in small-to-medium diameter DRG neurons and, when injected 
intrathecally (i.t.), produces a chemically-induced form of neuropathic pain that is 
dependent on LPA1 receptor activation38, 39.  17-PT PGE2 is a selective agonist for 
Gq-coupled prostanoid receptors, a class of receptors that are implicated in pain 
hypersensitivity following inflammation87-90.  Following stimulation with LPA or 17-PT 
PGE2, calcium responses (quantified as area under the curve) were blunted in 
Pip5k1c+/- neurons compared to WT controls (Figure 2.5A-2.5D).  Importantly, these 
signaling deficits could be fully restored to WT levels by delivering excess PIP2 into 
Pip5k1c+/- neurons just prior to imaging (Figure 2.5A-2.5D).  These data strongly 
suggest that the signaling deficits observed in Pip5k1c+/- neurons were the result of 
reduced PIP2 levels and were not due to poor cell health or PIP2-independent 
signaling deficits.  Moreover, KCl-evoked Ca2+ responses were not altered, further 
indicating deficits were not due to cell health (Figure 2.5A, data not shown).  
Importantly, LPA or 17 PT-PGE2-evoked calcium responses in non-neuronal cells 
was not reduced, suggesting neuronal-specific deficits.  The percentage of neurons 
responding to either ligand (LPA responders:  mean 22.2 ± 2.9% for WT and 24.1 ± 
3.7% for Pip5k1c+/-; 17-PT PGE2 responders:  6.0 ± 1.2% for WT and 4.7 ± 1.1% for 
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Pip5k1c+/-) and the average diameter of responding neurons was not significantly 
different between WT and Pip5k1c+/- cultures (data not shown).  We also found that 
delivering excess PIP2 into WT neurons did not elevate LPA or 17-PT PGE2 evoked 
calcium responses beyond control levels, suggesting that PIP2 levels are already 
saturated in WT neurons under our culture conditions.  Collectively, our data reveal 
that PIP5K1C regulates signaling downstream from two pronociceptive receptors, 
one associated with neuropathic pain and the other with inflammatory pain.  
Moreover, rescue experiments revealed that Pip5k1c regulates calcium signaling in 
DRG neurons via a PIP2-dependent mechanism, placing PIP5K1C upstream of 
multiple signaling pathways implicated in peripheral sensitization. 
 
Pip5k1c haploinsufficiency reduces ligand-induced nocifensive behaviors 
LPA and 17-PT PGE2 induce GPCR-mediated nociceptive responses when 
injected into the hindpaw and serve as a model of acute ligand-mediated nociceptive 
pain87, 91.  To determine if these compounds signal less effectively in Pip5k1c+/- mice, 
we injected LPA (4.1 µg) or 17-PT PGE2 (1.2 µg) into one hindpaw then monitored 
duration of licking for 5 minutes.  We found that Pip5k1c+/- mice spent less time 
licking their ligand-injected hindpaws when compared to WT littermate controls 
(Figure 2.5E), indicating reduced nociceptive responses to noxious chemical stimuli. 
 
 
 
 35 
Pip5k1c haploinsufficiency attenuates ion channel-mediated neuronal 
excitability  
In addition to regulating GPCR and TRPV1 activity that mediates nociceptive 
sensitization, PIP2 is also required for a variety of ion channels that modulate 
neuronal excitability and more importantly, hyperexcitability following nerve injury 
and inflammation.  Since membranous PIP2 was reduced by ~50% and PIP2-
dependent GPCR and TRPV1 signaling was reduced in Pip5k1c+/- neurons, we 
hypothesized that PIP2-dependent ion channel activity would also be attenuated.  To 
test this hypothesis, we first examined intrinsic neuronal excitability, which is 
mediated by a variety of PIP2-dependent ion channels23, 26, 62.  We assessed intrinsic 
excitability using whole cell recordings and quantified action potential firing rates 
(spikes per second) following current injections from 50 to 250 pA in small diameter 
(capacitance <20 pF; presumably nociceptive) neurons cultured from adult 
Pip5k1c+/- and WT mice. We observed that Pip5k1c+/- neurons were significantly less 
excitable (~30% reduction) at current injections ≥100 pA compared to neurons 
cultured from WT mice (Figure 2.6A and 2.6B).  The addition of PIP2 to the internal 
pipette solution completely restored excitability of Pip5k1c+/- neurons to WT levels 
suggesting that deficits in neuronal excitability are a direct result of decreased PIP2 
levels (Figure 2.6A and 2.6B).  These data are consistent with reduced activity of ion 
channels that mediate excitability through PIP2 dependent mechanism(s) 26. 
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Pip5k1c haploinsufficiency alters actin and tubulin cytoskeletal dynamics 
PIP2 is also important for actin assembly and polymerization at the membrane 
via interactions with actin binding proteins, such as ezrin 2 and vinculin 92.  
Furthermore, PIP5K1C facilitates actin organization at the membrane via 
interactions with the protein, talin 93.  Thus, we investigated filamentous actin (F-
actin) staining at the membrane in Pip5k1c+/- and WT neurons using phalloidin, a 
specific antibody for F-actin (Figure 2.7A).  Quantification of the membrane to 
cytoplasm ratio of F-actin in dissociated DRG neurons revealed that Pip5k1c+/- 
neurons have decreased membrane F-actin compared to WT neurons (Figure 2.7B).  
This finding is consistent with previous findings that sequestration of PIP2 using a 
pleckstrin homology domain of phospholipase Cδ (PLCδ-PH) reduced filamentous 
actin at the membrane 65.  Actin organization at the cell membrane was partially 
restored in Pip5k1c+/- neurons incubated with PIP2 suggesting that PIP5K1C 
regulates actin organization via mechanism(s) that are both independent of and 
dependent upon catalytic activity (data no shown).   
Tubulin, the main constituent of cytoskeletal microtubules, also directly 
interacts with PIP2 to regulate stability and functionality of ion channels at the 
membrane and PLC-catalyzed GPCR signaling29, 32, 33.  Therefore, we sought to 
determine the extent to which tubulin was affected as a result of Pip5k1c 
haploinsufficiency and resulting reductions in PIP2.  Immunocytochemical analysis 
with an antibody specific for neuronal beta III tubulin revealed that tubulin protein 
expression is increased by ~35% in Pip5k1c+/- neurons compared to WT controls 
(Figure 2.7C and 2.7D).  A similar increase was observed at the RNA level using 
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high-throughput RNA sequencing (RNAseq; 30.6% increase; data not shown).  
Notably, genes that increased by at least 50% in Pip5k1c+/- DRG compared to WT 
DRG were clustered using the database for annotation, visualization, and integrated 
discover (DAVID).  The top gene cluster (most enriched functional-related gene 
group) were genes involved in the cytoskeleton and contractile fibers (data not 
shown). Due to the availability of antibodies, we focused our immunocytochemical 
investigation of the cytoskeleton on actin and tubulin.  Taken together, our 
immunocytochemical and RNA sequencing data suggest that Pip5k1c 
haploinsufficiency increases tubulin expression.  Furthermore, taken together with 
our actin data, these data indicate that at least two important cytoskeletal proteins 
are altered as a result of Pip5k1c haploinsufficiency.  
Collectively, our in vitro studies with ion channels and GPCR-mediated 
calcium signaling, cytoskeletal filament makers, and neuronal excitability reveal that 
Pip5k1c centrally regulates pronociceptive signaling via PIP2-dependent 
mechanism(s) (Figure 2.8).  These data suggest that any one or combination of 
these deficits would result in reductions in nociceptive sensitization in models of 
chronic pain (Figure 2.8). 
 
Pip5k1c haploinsufficiency attenuates thermal and mechanical sensitization in 
models of chronic pain 
Since pronociceptive receptors and ion channels signaled less effectively in 
DRG neurons, we hypothesized that thermal and mechanical sensitization would be 
blunted in Pip5k1c+/- mice following inflammation or injury.  Indeed, it is well 
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established that pronociceptive receptor activation can sensitize animals to noxious 
thermal and mechanical stimuli 3, 6.  Thermal hyperalgesia and mechanical allodynia 
were enduringly attenuated in Pip5k1c+/- mice in models of chemically induced 
neuropathic pain (i.t. injection of 1 nmol LPA), neuropathic pain caused by spared 
nerve ligation and inflammatory pain following an intraplantar injection of complete 
Freund’s adjuvant (CFA) (Figure 2.9A-F).  There were no significant differences in 
the contralateral (non-inflamed/non-injured) paw between WT and Pip5k1c+/- mice, 
and there were no significant differences in either paw at baseline (i.e. prior to LPA 
injection, nerve injury, or inflammation).  Taken together, these data suggest that 
Pip5k1c regulates nociceptive sensitization in three different models (and two types) 
of chronic pain, with initiating events at three different anatomical locations (spinal, 
peripheral nerves and hindpaw). 
 
Phenotypes of Pip5k1c+/- are not due to motor impairment, loss of nociceptive 
neurons, or synaptic transmission deficits. 
The observed behavioral phenotypes were not due to motor impairment, as 
there were no significant differences between WT and Pip5k1c+/- mice in the rotarod 
assay (Figure 2.10A).  Additionally gait (stride or stance) and responses to 
mechanical stimuli (innocuous touch and von Frey filaments) were not impaired in 
Pip5k1c+/- mice (Figure 2.10B-D).   
These behavioral phenotypes were not due to a developmental loss of 
nociceptive neurons or terminals in spinal cord of Pip5k1c+/- mice (quantified by 
immunostaining for CGRP and IB4-binding, markers of nociceptive neurons; Figure 
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2.11A-J).  Moreover, these phenotypes were not due to impaired excitatory synaptic 
transmission between sensory neurons and spinal dorsal horn neurons, assessed by 
measuring excitatory field potential (fEPSP) amplitude in spinal cord slices after 
stimulating the dorsal root with a suction electrode75.  Specifically, we found no 
significant differences between genotypes in fEPSP amplitude at different stimulus 
strengths (Figure 2.11K), following synaptic depletion (Figure 2.11L and 2.11M) or 
during synaptic recovery (Figure 2.11N).  These data also ruled out the possibility 
that synaptic transmission or synaptic vesicle trafficking was impaired in Pip5k1c+/- 
mice.  Instead, our data suggest that the observed behavioral phenotypes reflect 
attenuated PIP2-dependent molecular mechanism(s). 
 
Discussion 
Nerve injury and inflammation result in peripheral nociceptive sensitization via 
activation and modulation of pronociceptive receptors and ion channels that regulate 
neuronal excitability3, 6, 10, 11.  Although these receptors and ion channels depend on 
PIP2 for activity and previous data suggested that reductions in PIP2 could reduce 
nociceptive sensitization84, it was unknown which kinase was responsible for the 
majority of PIP2 production in nociceptive neurons.  Our studies with Pip5k1c+/- mice 
reveal that PIP5K1C is the predominant PIP2 synthesizing enzyme and generates at 
least half of the PIP2 in the DRG.  Our studies provide the first evidence that 
reductions in the catalytic activity of PIP5K1C attenuate pronociceptive signaling and 
nociceptive sensitization in rodent models of chronic pain.  Importantly, our in vitro 
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studies with cultured DRG neurons reveal that PIP5K1C regulates at least three 
different mechanisms of pronociceptive signaling via PIP2-dependent processes.  
Furthermore, our studies reveal that Pip5k1c haploinsufficiency selectively 
reduces PIP2 in adult DRG without altering PIP2 levels in adult brain or spinal cord 
making it unlikely that PIP2-dependent reduction in thermal and mechanical 
nociceptive sensitization in rodent models of chronic pain is due to PIP2 decreases 
in other regions of the nervous system.  In support of this, previous studies by Di 
Paolo et al. indicated there were no synaptic transmission deficits in Pip5k1c+/- 
cortical neurons.  Furthermore, our in vitro studies reveal attenuated GPCR- and 
TRPV-mediated calcium signaling and ion channel-mediated neuronal excitability in 
DRG neurons and no deficits in synaptic transmission in the spinal cord.  Taken 
together, these data support the hypothesis that reduced PIP5K1C and subsequent 
reductions in PIP2 in the DRG are responsible for the antinociceptive phenotypes 
observed in Pip5k1c+/- mice.   
Thermal and mechanical sensitization following LPA-induced neuropathic 
pain was prevented in Pip5k1c+/- mice.  In contrast, our studies did not show that 
sensitization could be blocked entirely (maintain baseline withdrawal latency and 
threshold) in Pip5k1c+/- mice following SNI or CFA.  This could reflect the fact that 
GPCR- and ion channel-mediated signaling was reduced, but not eliminated, in 
neurons from Pip5k1c+/- mice.  Moreover, there are likely additional enzymes in DRG 
that generate PIP2 and contribute to pronociceptive receptor signaling.  Indeed, PIP2 
levels were not reduced to zero in DRG from Pip5k1c+/- or Pip5k1c-/- (embryonic) 
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mice.  It is likely there are additional signaling pathways and cellular mechanisms 
that contribute to nociceptive sensitization independent of PIP5K1C and PIP2 3, 6. 
 
Pip5k1c regulates pronociceptive GPCR and ion channel signaling via PIP2-
dependent processes. 
 Our in vitro studies with cultured DRG neurons reveal a critical regulatory role 
of PIP5K1C in three different pronociceptive signaling processes.  First, PIP5K1C 
modulates TRPV1-mediated signaling which is important for the detection of noxious 
stimuli and physiological function of the peripheral nociceptive system.  Second, 
PIP5K1C regulates GPCR signaling that mediates nociceptive sensitization following 
nerve injury and inflammation.  Lastly, PIP5K1C regulates ion channels that mediate 
neuronal hyperexcitability and long-lasting adaptations of the peripheral circuitry 
following nerve injury and inflammation.  Importantly, our data suggest all three 
processes are dependent on the catalytic activity of PIP5K1C because exogenous 
delivery of PIP2 completely restored all signaling deficits. 
 Although the mechanism(s) by which PIP5K1C regulates pronociceptive 
signaling are PIP2-dependent, the exact PIP2-dependent mechanism(s) still need to 
be elucidated.  We speculate that the signaling deficits observed in Pip5k1c+/- mice 
result primarily from the necessity of PIP2 hydrolysis for efficient GPCR signaling and 
from direct regulatory interactions of PIP2 with ion channels.  PIP2-dependent 
reductions in GPCR signaling are likely due to attenuation of PLC-catalyzed 
hydrolysis of PIP2 into DAG and IP3, downstream mediators required for GPCR-
mediated calcium release.  Similarly, reductions in PIP2-dependent TRPV1-mediated 
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calcium signaling and ion channel-mediated neuronal excitability are likely due to 
direct regulatory interactions of PIP2 with ion channels16, 21, 23, 25, 62.  However, we 
cannot rule out other potential PIP2-dependent processes that also influence 
signaling of GPCRs and ion channels.   
For example, our studies reveal that actin and tubulin expression is altered in 
Pip5k1c+/- mice, both of which interact with PIP2 to indirectly modulate signaling.  It is 
reasonable to believe that increased tubulin expression and altered expression 
pattern of actin contribute to the observed signaling deficits.  In fact, increases in 
tubulin have been shown to inhibit PLC-mediated GPCR signaling29, 32.  In addition, 
intact microtubules are required for TRPV1 functionality following activation33.  Thus, 
studies on the extent to which increases in beta-III tubulin effect microtubule 
polymerization and depolymerization dynamics are needed to determine how 
TRPV1 and other ion channel functionality may be altered.  Lastly, it has been 
reported that an intact actin cytoskeleton is required for prostaglandin-mediated 
inflammatory pain40 indicating that altered PIP2-actin interactions may contribute to 
the observed prostaglandin-mediated GPCR signaling deficits.  Determining the 
exact mechanism(s) and to what extent each mechanism contributes to the 
observed signaling deficits is beyond the scope of this project and will require the 
development of new assays and techniques to separate each of the mechanisms.  
Collectively, our data indicate that PIP2-dependent mechanism(s) regulate 
pronociceptive signaling but the extent to which each mechanism is involved 
requires further investigation. 
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Pip5k1c haploinsufficiency attenuates PIP2-dependent nociceptive 
sensitization in models of chronic pain 
 In addition to deficits in pronociceptive signaling in vitro, we observed 
reductions in nociceptive sensitization in Pip5k1c+/- mice in vivo.  Acute nociceptive 
responses including detection of noxious heat and ligand-evoked nocifensive 
behaviors were reduced in Pip5k1c+/- mice.  Ligand-evoked nocifensive licking in 
response to LPA and 17-PT PGE2 was significantly reduced in Pip5k1c+/- mice; 
however nocifensive responses to capsaicin were not reduced.  In contrast, 
responses to noxious thermal (>43°C) stimuli were reduced, indicating that PIP5K1C 
may contribute to differential signaling mechanisms following chemical or thermal 
activation of TRPV1.  Taken together, our data suggest that the innate defensive 
mechanism of the nociceptive system is regulated by PIP5K1C and should be 
considered when evaluating PIP5K1C as a target for analgesic drug development. 
 The most profound reductions in nociceptive responses of Pip5k1c+/- mice 
were observed in models of chronic inflammatory and neuropathic pain.  Thermal 
and mechanical nociceptive sensitization were attenuated in three models of chronic 
pain, LPA-induced neuropathic pain, SNI-induced neuropathic pain and CFA-
mediated inflammatory pain, with initiating events at three different anatomical 
locations, spinal, peripheral nerve, and hindpaw, respectively.  Importantly, 
reductions in thermal and mechanical nociceptive sensitization in Pip5k1c+/- mice in 
the three chronic pain models were completely restored to WT levels via exogenous 
intrathecal delivery of PIP2 just prior to inflammation or injury.  These data suggest 
that PIP5K1C regulation of nociceptive sensitization is dependent upon the catalytic 
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activity and subsequent PIP2 concentrations at the time of injury or inflammation.  
Indeed, these findings are consistent with previous studies that indicated indirect (via 
adenosine receptor activation) reductions in PIP2 concentration at the time of injury 
or inflammation reduced thermal and mechanical sensitization in modes of chronic 
pain84.  Taken together, our studies validate PIP5K1C as a novel regulatory kinase 
in nociceptive sensitization and suggest there is enormous potential for developing 
PIP5K1C inhibitors as treatments for chronic pain.  
 
Implications for humans carrying one or two non-functional mutation(s) in 
PIP5K1C 
The cytoskeleton is made up of three types of filaments, microtubules (made 
from tubulin), microfilaments (made from actin) and intermediate filaments.  Pip5k1c 
haploinsufficiency results in the alteration of actin and tubulin expression, two major 
components of microfilaments and microtubules, respectively.  These changes are 
most likely due to reduced synthesis of PIP2, which interacts with both actin and 
tubulin to maintain stable cytoskeletal structure and mediate signaling27, 48.  
Neuronal-specific beta-III tubulin expression is increased by approximately 30% 
while the expression pattern of actin is altered in Pip5k1c+/- DRG neurons.  
Specifically, filamentous actin is reduced at the plasma membrane in Pip5k1c+/- DRG 
neurons.  Importantly, actin serves as a scaffolding protein for tropomyosin and 
troponins during muscle contraction.   
Human lethal congenital contracture syndrome type 3 (LCCS3) results from 
homozygous mutation in PIP5K1C in which aspartic acid 253 is mutated to 
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asparagine and renders the kinase inactive.  LCCS3 is characterized by severe fetal 
akinesia, joint contractures, and muscle atrophy and results in death either 
embryonically or within 24 hours of birth.  This mirrors the phenotype of Pip5k1c-/- 
mice, which also die within 24 hours of birth due to immobility and an inability to 
feed45, 94.  Di Paolo et al. (mouse phenotype) and Narkis et al. (human phenotype) 
attribute the perilethality phenotype to reduced PIP5K1C-mediated synaptic vesicle 
release and endocytosis that is blunted following homozygous mutation.  However, 
the link between homozygous mutations in PIP5K1C and the muscle-contraction 
based LCCS3 has never been investigated.  
Although PIP5K1C expression is considered limited to neuronal tissue in mice 
and has been previously reported as having minimal expression in skeletal muscle45, 
51, the expression profile in humans has not been determined.  Furthermore, 
alterations in cytoskeletal proteins following mutations of Pip5k1c/PIP5K1C may be 
genome-wide and not tissue specific.  Alternatively, the actin and tubulin phenotypes 
could be contributing to the phenotype via alterations in neuronal projections from 
the nervous system into the muscle.  Nerve innervation into the muscle is required to 
transmit signals (in the form of action potentials) from the brain to the muscle to 
initiate contraction.   
The exact mechanism by which muscle contraction is altered in the human 
phenotype are not known; however, these data suggest a link between alterations in 
cytoskeletal filaments that are required for muscle contraction and the LCCS3 
phenotype that results from homozygous PIP5K1C mutation.  A greater 
understanding of PIP5K1C in human physiology (particularly muscle and neuronal 
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tissue) is needed before further conclusions can be made.  Interestingly, mutations 
in cytoskeletal filament genes such as alpha-actin (ACTA1) and skeletal troponin T 
(TNNT) have been implicated in arthrogryposis disorders similar to LCCS395, 96.  This 
further supports the hypothesis that alterations in cytoskeletal dynamics as a result 
of mutations in PIP5K1C likely contribute to the LCCS3 phenotype. 
Importantly, although our preliminary studies with actin and tubulin may 
provide a potential link to the human LCCS3 phenotype as a result of homozygous 
mutation, muscle-contracture phenotypes are not observed in adult Pip5k1c+/- mice 
and were not reported in humans carrying a mutation in one allele of PIP5K1C.  
Additionally, the muscle/joint contractures and muscle atrophy are likely due to 
reduced PIP2 synthesis during embryonic development.  Thus, we conclude that 
alterations to muscle contraction are not contributing to the observed antinociceptive 
phenotypes of Pip5k1c+/- mice.  Rather, the antinociceptive effects are due to 
reduced PIP2-dependent pronociceptive signaling and sensitization.  
 Interestingly, Israeli Bedouins that live in the Negev desert, an environment 
where somatosensory stimuli are extreme, frequently harbor a heterozygous 
mutation in PIP5K1C (LCCS3 that results from a homozygous mutation in PIP5K1C 
is prevalent in this community) 94.  Our studies with Pip5k1c+/- mice reveal reduced 
nociceptive responses to various somatosensory stimuli, suggesting that humans 
with one mutated allele may also have reduced nociceptive responses, which could 
provide a survival advantage in what is known to be an extreme environment.  
Although our data suggest a link, additional studies are needed to implicate 
PIP5K1C in human nociceptive processing pathways. 
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Figures 
 
Figure 2.1.  PIP5K1C is the predominant PIP5K1 isoform in adult nociceptive 
DRG neurons.   
(A-C) In situ hybridization with gene-specific probes using sections from adult mouse 
lumbar DRG.  Scale bar, 50 µm.  (D,E) Double fluorescence in situ hybridization 
using adult lumbar DRG.  Confocal images.  Scale bar, 50 µm. (F,G) Sections from 
adult mouse DRG were immunostained for (F) PIP5K1C (c1 isoform) and (G) NeuN, 
merged.  Confocal images.  Scale bar, 50 µm. 
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Figure 2.2.  PIP5K1C generates at least half of all PIP2 in embryonic mouse 
DRG. 
(A, B) PIP5K1C protein levels in the DRG of WT, Pip5k1c+/-, and Pip5k1c-/- 
embryonic (E17.5-18.5) mice relative to β-actin.  (A) Representative western blots 
and (B) quantification; n=3 embryos per genotype.  (C) PIP2 levels in embryonic 
(E17.5-18.5) DRG quantified by mass ELISA from WT, Pip5k1c+/-, and Pip5k1c-/- 
mice.  n=10 embryos per genotype. 
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Figure 2.3 PIP5K1C generates at least half of all PIP2 in adult mouse DRG.   
(A, B) PIP5K1C protein levels in adult DRG of male Pip5k1c+/+ and Pip5k1c+/- mice 
relative to β-actin.  (A) Western blots and (B) quantification; n=3 per genotype.  (C) 
PIP2 levels in DRG, spinal cord, and brain (cerebral cortex) of adult male Pip5k1c+/+ 
and Pip5k1c+/- mice, quantified by mass ELISA.  n=10 mice per genotype.  (D) 
Representative images of membrane PIP2 staining in small diameter DRG neurons 
cultured from Pip5k1c+/+ and Pip5k1c+/- adult mice relative to NeuN and (E) 
quantification of the average perimeter (membrane) intensity.  n=28 small diameter 
neurons quantified per genotype.  All data are mean ± SEM.  *p<0.05, ***p<0.0005. 
 
 50 
 
Figure 2.4.  Pip5k1c haploinsufficiency attenuates TRPV1-mediated signaling 
and acute nociceptive sensitivity to heat.   
(A) Calcium responses and (B) quantification (area under the curve, AUC).  Cultured 
adult DRG neurons were stimulated with 1 µM capsaicin for 30 s, washed with 
HBSS for 4.5 minutes to remove the ligand, then stimulated for 30 s with 100 mM 
KCl to confirm neuron identity.  Cultures were incubated with 2 µM carrier or 2 µM 
Carrier + 2 µM PIP2 for 15 minutes prior to calcium imaging.  Number of neurons 
quantified is indicated in the bar graph.  (C) WT and Pip5k1c+/- mice were restrained 
by scruffing and the right hindpaw was placed on a metal surface of the indicated 
temperature.  The latency for the animal to withdrawal (lift, shake, or jump) its paw 
was recorded.  (B,C) All data are mean ± SEM.  *p<0.05, **p<0.005, ***p<0.0005.  
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Figure 2.5.  Pip5k1c haploinsufficiency reduces ligand-evoked nociceptive 
signaling in vitro and nocifensive licking in vivo.   
(A,C) Calcium responses and (B,D) quantification (area under the curve, AUC).  
Cultured adult DRG neurons were stimulated with (A, B) 10 µM LPA or (C, D) 10 µM 
 52 
17-PT-PGE2 for 90 s, washed with HBSS for 120 s to remove the ligand, then 
stimulated for 30 s with 100 mM KCl to confirm neuron identity (not shown for 17-PT 
PGE2).  Cultures were incubated with 2 µM carrier or 2 µM Carrier + 2 µM PIP2 for 
15 minutes prior to calcium imaging.  Number of neurons quantified is indicated in 
the bar graph.  (E) Time spent licking for the first 5 minutes after injecting vehicle, 
4.1 µg LPA, or 1.2 µg 17-PT PGE2 into the left hindpaw of adult WT and Pip5k1c+/- 
male mice.  n=10 mice per genotype per agonist.  (A-E) Data are mean ± SEM.  
*p<0.05, **p<0.005, ***p<0.0005. 
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Figure 2.6.  Pip5k1c haploinsufficiency attenuates PIP2-dependent ion channel-
mediated neuronal excitability.   
(A) Representative action potentials following 100 pA current injection.  (B) 
Quantification of firing rate (action potential spikes per second) for neurons cultured 
from Pip5k1c+/+ and Pip5k1c+/- adult mice.  Carrier (10 µM) or Carrier (µM) + PIP2 (10 
µM) were interleaved in the internal pipette solution.  n=25-40 neurons per genotype.  
Data are mean ± SEM.  ***p<0.0005. 
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Figure 2.7.  Pip5k1c haploinsufficiency alters the expression of cytoskeletal 
proteins.   
(A) Representative images of F-actin (phalloidin) staining (B) and quantification of 
the membrane to cytoplasmic ratio in small diameter DRG neurons cultured from 
Pip5k1c+/+ and Pip5k1c+/- adult mice.  Number of neurons quantified indicated in the 
bargraph.  (C) Representative images of beta-III tubulin staining (D) and 
quantification of the membrane to cytoplasmic ratio in small diameter DRG neurons 
cultured from Pip5k1c+/+ and Pip5k1c+/- adult mice. Number of neurons quantified 
indicated in the bargraph.  (B, D) All data are mean ± SEM.  ***p<0.0005.  
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Figure 2.8.  Schematic representation of all PIP2-dependent mechanisms 
altered by Pip5k1c haploinsufficiency. 
Model.  PIP5K1C generates PIP2 that is hydrolyzed downstream of pronociceptive 
GPCR and ion channel activation.  Ca2+ influx (from GPCRs and ion channels) and 
PKC activation of MAPKs contribute to nociceptive sensitization 3, 6.  PIP2 also 
regulates actin assembly, tubulin-dependent PLC-mediated signaling and GPCR 
and ion channel stability.  Pip5k1c haploinsufficiency reduces the amount of PIP2 
that is available for signaling in DRG neurons. 
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Figure 2.9.  Pip5k1c haploinsufficiency reduces PIP2-dependent thermal and 
mechanical sensitization in models of chronic inflammatory and neuropathic 
pain.  
(A) Thermal and (B) mechanical sensitivity in the chemically induced (LPA; 1nmol; 
intrathecal) neuropathic pain model in adult male Pip5k1c+/+ and Pip5k1c+/- mice.  
Intrathecal injection of either carrier (0.3 nmol) or carrier (0.3 nmol) + PIP2 (0.3 nmol) 
administered immediately prior to LPA injection.  n=10 for WT+ Carrier and n=20 for 
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Pip5k1c+/- + Carrier and Pip5k1c+/ - + PIP2 (C) Thermal and (D) mechanical sensitivity 
in the spared nerve injury neuropathic pain model. Contralateral paw was not injured 
and served as a control.  n=6 for WT + Carrier, n=10 for Pip5k1c+/- + Carrier and n=7 
for Pip5k1c+/- + PIP2.  (E) Thermal and (F) mechanical sensitivity in the CFA chronic 
inflammatory pain model.  CFA (20 µL) was injected into one hindpaw.  Contralateral 
paw was not injected and served as a control.  n=10 for WT + Carrier, n=20 for 
Pip5k1c+/- + Carrier and n=10 for Pip5k1c+/- + PIP2.  Intrathecal injection of either 
carrier (0.3 nmol) or carrier (0.3 nmol) + PIP2 (0.3 nmol) administered immediately 
prior to and 2 hours following (C,D) injury or (E.F) inflammation.  (A-F) All data are 
mean ± SEM.  *p<0.5, ***p<0.0005 (one-way ANOVA).  Red asterisks indicate 
significance between Pip5k1c+/- mice and WT mice receiving carrier only.  Blue 
asterisks indicate significance between Pip5k1c+/- mice receiving carrier and 
Pip5k1c+/- mice receiving carrier + PIP2.  
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Figure 2.10.  Pip5k1c haploinsufficiency does not alter motor function, gait or 
low-threshold (innocuous) mechanoreception.   
(A) Rotarod test of motor function.  Three trials with adult WT and Pip5k1c+/- male 
littermates.  n=10 mice per genotype.  (B,C) Gait analysis with adult WT and 
Pip5k1c+/- male mice.  (B) Representative gait measurements showing stride and 
stance and (C) quantification.  Five stride and five stance measurements per animal.  
n=10 male mice per genotype.  (D) Withdrawal frequency of each hindpaw to an 
innocuous mechanical stimulus (cotton swab).  5 trials per hindpaw.  n=10 male 
mice per genotype (A-D) All data are mean ± SEM.  No significant differences 
between genotypes in any of these assays. 
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Figure 2.11.  Nociceptive neuron markers and synaptic transmission between 
sensory neurons and spinal cord are not affected in Pip5k1c+/- mice.   
(A-J) IB4-binding (nonpeptidergic marker, blue) and immunofluorescence staining of 
CGRP (peptidergic marker; green) and NeuN (pan-neuronal marker, red).  (A-D; F-I) 
lumbar DRG and (E,J) superficial dorsal horn of adult male WT and Pip5k1c+/- 
littermates.  Insets show average percentage of IB4+ or CGRP+ neurons relative to 
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NeuN (± SEM).  No significant differences between genotypes.  Scale bar in (G, I, 
and J) is 50 µm.  (K-N) Field excitatory postsynaptic potential (fEPSP) recordings in 
spinal cord slices (lamina II) from adult male WT and Pip5k1c+/- mice.  (K) fEPSP 
amplitude as a function of stimulus strength.  (L) 1 Hz synaptic depletion.  1.0 mA 
stimulation at 1 Hz for 40 trials to deplete neurotransmitter.  fEPSP peak amplitude 
was measured for each trial and plotted as trial number.  (M) 10 Hz synaptic 
depletion.  1.0 mA stimulation at 10 Hz for 400 trials to deplete 
neurotransmitter.  fEPSP peak amplitude was measured for each trial and plotted as 
trial number.  (N) Synaptic recovery following 10 Hz depletion.  Immediately after 
synaptic depletion, the slices were stimulated at 1.0 mA stimulation at 0.1 Hz for 10 
minutes to assess recovery from synaptic depletion.  n=12 WT, n=10 Pip5k1c+/- 
slices.  No significant differences between genotypes (one-way ANOVA).   
 
  
CHAPTER III 
 
SENSORY NEURON-SPECIFIC GENETIC DELETION OF PIP5K1C IN MICE 
RESULTS IN PROPRIOCEPTIVE ABNORMALITIES 
 
Introduction 
 Our studies in Chapter II focused on elucidating the role of PIP5K1C in 
nociceptive signaling and sensitization using a Pip5k1c haploinsufficiency model in 
which one allele of Pip5k1c was genetically deleted in all cells45.  Given that 
pronociceptive receptors and ion channels located on the membrane of DRG 
neurons play a critical role in peripheral sensitization after nerve injury and 
inflammation, this chapter focuses on our characterization efforts in the DRG3, 6.  
Importantly, our previous studies revealed selective decreases in PIP2 levels within 
the DRG while PIP2 levels in the spinal cord and frontal cerebral cortex were 
unaffected in Pip5k1c+/- mice (Figure 2.3).  In addition, we showed that synaptic 
transmission in the spinal cord was unaffected (Figure 2.9) and that intrathecal 
delivery of PIP2 rescued thermal and mechanical nociceptive sensitization defects 
observed in Pip5k1c+/- mice.  Significantly, these intrathecal injections specifically 
increased PIP2 concentration in the DRG and not in the spinal cord (Figure 3.1).  
Collectively, these studies led us to hypothesize that PIP5K1C regulates nociceptive 
signaling and sensitization via PIP2-dependent mechanisms within the DRG.   
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Although our previous data suggest that PIP5K1C regulates peripheral 
nociceptive sensitization within the DRG and that PIP2 reductions are DRG-specific 
in the haploinsufficiency model, we cannot completely rule out the possibility that 
deletion of the PIP5K1C protein alone is effecting activity, given that PIP5K1C 
regulates many cellular processes via mechanisms that may be independent of 
catalytic activity47-49, 97.  In addition, we cannot rule out the possibility that PIP5K1C-
and PIP2-dependent mechanisms are contributing to the observed phenotypes in 
tissues or cell types that were not tested.  Thus, we sought to test our hypothesis 
using mice with conditionally deleted Pip5k1c using Cre recombinase (Cre) driven by 
the advillin promoter, which is exclusively expressed in sensory neurons of the DRG 
and trigeminal ganglia.  Here, we report that although Advillin-Cre can be used to 
selectively reduce Pip5k1c in sensory neurons, mice lacking both alleles of Pip5k1c 
in the DRG exhibit a proprioceptive phenotype, rendering them unusable in standard 
nociceptive assays.  In contrast, conditional Pip5k1c heterozygotes do not exhibit 
the proprioceptive phenotype and are currently being used to test our hypothesis 
that PIP5K1C reductions in the DRG mediate the observed reductions in peripheral 
sensitization. 
 
Methods 
Animals 
All procedures involving vertebrate animals were approved by the Institutional 
Animal Care and Use Committee at the University of North Carolina at Chapel Hill.  
We obtained knockout-first, conditional-ready Pip5k1c mice from the UC Davis 
  
63 
knockout mice project (komp.org) via the Wellcome Trust Sanger Institute.  Exon 5 
which, encodes a portion of the catalytic domain, was flanked by LoxP sites.  Upon 
arrival, the first litter of offspring was used for beta-galactosidase staining to confirm 
presence of transgene, via the presence of LacZ as confirmed by genotyping.  Mice 
containing the transgene were then crossed with FlpE mice to remove the neomycin 
resistance cassette.  Mice positive for the transgene with confirmed deletion of the 
neomycin cassette were crossed with Advillin-CRE mice (Adv) to conditionally delete 
Pip5k1γ only in sensory neurons98-100.  The advillin promoter drives expression of 
Cre in sensory neurons only (DRG and trigeminal ganglia) in the Advillin-CRE mice, 
which have been extensively characterized98, 100.  Mice were genotyped with the 
following primers (provided by Wellome Trust Sanger Institute): CAS_R1_Term: 
TCGTGGTATCGTTATGCGCC, Pip5k1c_Forward: TGGAGAGCATCTTCTTCCCC, 
Pip5k1c_Reverse: TAACCATCATCCCTCCCTCG, LacZ_Forward: 
ATCACGACGCGCTGTATC, and LacZ_Reverse: ACATCGGGCAAATAATATCG.  
Cas_R1_Term and Pip5k1c_Forward are used to observe a 210 base pair (bp) 
mutant band, Pip5k1c_Forward and Pip5k1c_Reverse are used to observe a 375 bp  
wild-type band. LacZ_Forward and LacZ_Reverse were used to confirm presence of 
LacZ prior to removal with FlpE mice.  Female Pip5k1cfl/fl, Advillin+/+ were crossed 
with male Pip5k1cfl/fl, AdvillinCre/Cre to produce the desired Pip5k1cfl/fl, Advillin Cre/+ 
knockout animals.  Pip5k1cwt/wt, Advillin Cre/+ (wt/wt) mice served as controls.  All 
mice were backcrossed to C57Bl/6 mice for at least 10 generations. 
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In situ hybridization 
Lumbar DRG were dissected from adult WT males 6-8 weeks old.  Gene-
specific probe preparation and in situ hybridization were performed as previously 
described69.  Briefly, tissue was mounted in TissueTek immediately following 
dissection and cryosectioned at 20 µm.  Non-isotopic in situ hybridization was 
performed using digoxigenin-labeled cRNA probes for Pip5k1c and standard nitro 
NBT and 5-bromo-4-chloro-3-indolyl phosphate BCIP stain.  In situ hybridization 
was completed by the UNC in situ hybridization core. 
 
Western blot analysis 
Lumbar DRG, lumbar spinal cord, and brain (frontal cortex) were dissected 
from adult male mice (6-8 weeks old) and embryos (E17.5-18.5).  Tissue lysates 
were prepared in RIPA buffer (50 mM Tris, 1% Triton X-100, 0.25% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM ethylenediaminetetraacetic acid 
and 150 mM sodium chloride) containing protease inhibitors (Roche Complete Mini 
Tablets, 11836153001 and 1 mM phenylmethylsulfonyl fluoride) and separated by 
SDS-PAGE.  Gels were transferred onto PVDF membranes and blocked with 5% dry 
milk (BioRad) in TBS-T (100 mM Tris, 165 mM sodium chloride, and 0.1% Tween 
20).  Primary antibodies were prepared in TBS-T containing 5% BSA.  PIP5K1C 
antibody (1:500) was a generous gift from P. De Camilli.  Anti-β-actin (1:3000, 
Abcam, ab6276) served as a loading control.  Secondary antibodies (1:10,000; Li-
Cor IRDye 680 and 800) were prepared in TBS-T containing 5% dry milk.   
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Immunohistochemistry 
Mice were sacrificed using pentobarbital.  Skin from the hindpaw (containing 
the volar pad, hairy skin, and glaborous skin) was dissected from adult (6-8 week 
old) male mice and prepared as described previously71, 72.  Briefly, tissues were 
immersion-fixed in 4% paraformaldehyde for 4 hours and cryopreserved in 30% 
sucrose at 4°C for 3 days.  Tissue was embedded in TissueTek and cryosectioned 
at 20 µm.  Sections were then immunostained and thaw mounted onto SuperFrost 
Plus slides.  The following primary antibodies were used for overnight incubations (at 
4°C): rabbit anti-PGP9.5 (1:500; Ultraclone) and mouse anti-NeuN (1:250; Millipore, 
MAB377).  Fluorescently conjugated secondary antibodies were purchased from 
Invitrogen and were used at 1:200 for for 2 hours at room temperature.  All staining 
solutions were made in TBST (0.05 M Tris, 2.7% NaCl, 0.3% Triton-X 100, pH 7.6).  
All images were obtained using a confocal microscope (Zeiss LSM 510). 
 
Behavioral Analysis 
Mice were observed for many days (starting from birth through adulthood) to 
monitor the proprioceptive phenotype.  Animals were photographed and videotaped 
to document the phenotype.  Gait measurements were taken by painting the 
hindpaws with ink and allowing the mice to walk in a straight line down an enclosed 
runway.  Stride was measured as the distance (in cm) between the left hindpaws (5 
measurements per animal were averaged).  Stance was measured as distance (in 
cm) between the left hindpaw and the subsequent step of the right hindpaw (5 
measurements per animal were averaged). 
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Results 
Pip5k1c is selectively eliminated in sensory neurons of Pip5k1cfl/fl mice 
crossed with Advillin-CRE. 
 Mice provided from the Wellcome Trust Sanger Institute were confirmed to 
have the desired transgene upon arrival via beta-galactosidase staining (data not 
shown).  These mice were crossed to FlpE mice (Jackson laboratory, 005703) to 
successfully remove the neomycin cassette, which was flanked by FRT sties (Figure 
3.2).  Mice bearing two copies of the floxed Pip5k1c allele in which the neomycin 
cassette was removed were crossed with Advillin-Cre mice to produce the desired 
Pip5k1cfl/fl, AdvillinCre/+ knockout mice (Figure 3.2).  Note that Pip5k1cfl/fl, AdvillinCre/+ 
knockout mice will be referred to as Pip5k1cfl/fl (or simply fl/fl) whereas the 
Pip5k1cwt/wt, AdvillinCre/+ controls will be referred to as wt/wt.  In situ hybridization 
using a specific Pip5k1c RNA probe (used in Chapter II) revealed dramatic 
decreases in Pip5k1c mRNA expression in the DRG but not in the spinal cord of 
Pip5k1cfl/fl mice compared to wt/wt controls, suggesting that selective deletion of 
Pip5k1c was successful at the level of mRNA (Figure 3.3A-D).  In addition, western 
blotting with a PIP5K1C-specific antibody revealed selective reductions of PIP5K1C 
protein in lumbar DRG but not lumbar spinal cord of Pip5k1cfl/fl mice compared to 
wt/wt mice, further suggesting that conditional deletion of Pip5k1c in sensory 
neurons only was successful (Figure 3.3E and 3.3F).  It must be noted that neither 
Pip5k1c mRNA nor PIP5K1C protein was completely eliminated in the DRG of 
Pip5k1cfl/f mice.  PIP5K1C protein levels were reduced by approximately 75% in the 
Pip5k1cfl/fl DRG compared to wt/wt controls (Figure 3.3F). 
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Pip5k1cfl/fl mice exhibit a hindlimb proprioceptive phenotype  
Although the use of Advillin-Cre appears to specifically eliminate PIP5K1C in 
sensory neurons, Pip5k1cfl/fl mice develop what has been characterized in the 
literature as a hindlimb proprioceptive phenotype101, 102.  The phenotype has been 
characterized as withdrawal of the hindlimbs close to the body when suspended by 
the tail (allowing the front paws to grip onto a wire surface), and awkward placement 
of the hindlimbs when sitting; both behaviors are exhibited by Pip5k1cfl/fl mice 
(Figure 3.4A and 3.4B).  These behaviors can be observed by P7 (7 days after 
birth).  Often, the Pip5k1cfl/f mice will extend their hindlimbs vertically by their ears, a 
behavior not typical of WT (or wt/wt) mice (data not shown).  Although certain 
proprioceptive behaviors were observed, there was no difference in gait (stride or 
stance—see methods for details) between Pip5k1cfl/fl mice and wt/wt controls (Figure 
3.4C).  Unfortunately, this proprioceptive phenotype makes it impossible to use 
these mice for standard nociceptive testing including the Hargreaves radiant heat 
test and electric von Frey mechanical test.  Furthermore, when using the standard 
scruffing technique to restrain animals, it was noted that there appears to be excess 
“loose” skin on the Pip5k1cfl/fl mice compared to wt/wt controls (data not shown).  
This prevented completion of all other standard nociceptive assays including the 
restrained hot plate and tail immersion tests.  Collectively, our behavioral analysis 
shows that phenotypes exhibited by Pip5k1cfl/fl mice are the same as those deemed 
as proprioceptive phenotypes in the literature and render these mice unusable for 
nociceptive studies101, 102.   
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Nerve innervation into the skin is reduced in Pip5k1cfl/fl mice  
Studies characterizing proprioceptive phenotypes in the literature have 
investigated these phenotypes by observing histochemical markers of nociceptive 
versus proprioceptive neurons, as well as nerve innervation from the DRG into 
various tissues including the skin101, 102.  Protein gene product 9.5 (PGP9.5) is a 
neuronal marker that can be used to visualize nerve innervation from the peripheral 
nervous system (DRG) into skin.  Given that all phenotypes in Pip5k1cfl/fl mice were 
observed in the hindlimbs, we evaluated PGP9.5 staining in the skin of the hindpaw.  
PGP9.5 staining in the hindpaw glabrous skin, the volar pad, and hairy skin of 
Pip5k1cfl/fl mice was dramatically reduced compared to wt/wt controls (Figure 3.5), 
although the differences cannot be easily quantified.  Interestingly, histochemical 
analysis of parvalbumin—a metabolic marker of proprioceptive DRG neurons that 
has been characterized as absent in mice with the reported proprioceptive 
phenotype—revealed no differences between Pip5k1cfl/fl mice and wt/wt controls 
(data not shown).  In addition, there were no histochemcial differences when staining 
with a nociceptive marker, CGRP (data not shown).  Taken together, our data 
suggests that neuronal development within the DRG is intact in both nociceptive and 
proprioceptive neurons but projection of DRG nerve terminals into the skin is 
disrupted. 
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Discussion 
 The peripheral sensitization that mediates persistent/chronic pain results from 
prolonged hyperexcitability of neurons found in the DRG.  Our previous data with 
global heterozygous Pip5k1c knockout mice suggested that reductions in PIP5K1C 
catalytic activity in the DRG significantly reduce peripheral sensitization (Chapter II); 
however, one allele of Pip5k1c was eliminated in all cells.  To further investigate the 
site of action of PIP5K1C deletion on the observed phenotypes, we aimed to 
specifically delete Pip5k1c in sensory neurons only.  Using a conditional deletion 
strategy, we reduced PIP5K1C expression in DRG and not in the spinal cord, 
suggesting successful targeting of sensory neurons using Advillin-CRE.  
Unfortunately, homozygous deletion of Pip5k1c in sensory neurons resulted in a 
profound proprioceptive defect that made nociceptive studies impossible.  We limited 
our in situ hybridization and Western blotting evaluations to the spinal cord and DRG 
due to the presence of this extreme phenotype and the fact that Advillin-CRE mice 
have been extensively characterized showing specific Cre expression in sensory 
neurons of the dorsal root and trigeminal ganglia with no expression of Cre in other 
areas of the mouse embryo including the spinal cord and brain 98, 100.   
Interestingly, behaviors observed in Pip5k1cfl/fl mice are characteristic of the 
reported hindlimb proprioceptive phenotype.  However, preliminary 
immunohistochemical analysis of lumbar DRG neurons, which are responsible for 
projections into the hindlimbs, did not show a loss of parvalbumin-positive neurons, 
which are characteristically eliminated in proprioceptive phenotypes previously 
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reported101, 102.  These data suggest that Pip5k1c elimination does not result in a 
loss of proprioceptive neurons, rather the proprioceptive phenotype is due to 
mechanisms independent neuron loss. 
 
PIP5K1C regulates DRG peripheral afferent innervation 
Detection of noxious stimuli begins at the site of injury or inflammation via the 
peripheral (or afferent) terminal of DRG neurons that innervate target tissues such 
as the skin6, 10.  Our immunohistochemical analysis of PGP9.5 staining in the 
hindpaw skin revealed dramatic, almost complete elimination, of peripheral terminal 
innervation from the DRG into the skin of Pip5k1cfl/fl mice.  PGP9.5 is a non-specific 
marker of nerve innervation; therefore, we cannot make any conclusions regarding 
the type of innervations that are lost (free nerve endings versus encapsulated, for 
example).  However, given the near-elimination of nerve endings in the glabrous skin 
and volar pad, it is reasonable to assume that both encapsulated (proprioceptive) 
and free nerve endings (nociceptive) are lost when Pip5k1c is reduced.  These data 
suggest that Pip5k1c elimination in DRG produces a proprioceptive phenotype due 
to reduced afferent extension into target tissue rather than loss of proprioceptive 
neurons as reported by other gene/protein deletions. 
PIP5K1C and PIP2 play important roles in both actin and tubulin dynamics in 
many cell types27, 29, 32, 48, 66, 103 including DRG (Chapter II).  Given that DRG afferent 
innervation into target tissues requires concerted rearrangements of actin filaments 
and microtubules104, and PIP5K1C-interacting proteins such as talin and vinculin, it 
is reasonable to speculate that the reduced nerve innervation observed in Pip5k1cfl/fl 
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mice may be due to alterations in PIP5K1C regulation of actin and tubulin dynamics 
similar to those observed in Pip5k1c+/- mice (Chapter II).  In support of this 
mechanism, cortical migration, another process that relies heavily on concerted 
cytoskeletal rearrangements, is disrupted when Pip5k1c is deleted using in utero 
electroporation of Pip5k1c small hairpin RNA (shRNA)83.  Extensive studies of actin 
and microtubule dynamics in Pip5k1cfl/fl mice are needed and may provide a starting 
point for beginning to understand the mechanism(s) underlying the disrupted nerve 
innervation.  
Neurotrophins (nerve growth factor, brain-derived growth factor, neurotrophin-
3 and neurotrophin-4) activate receptor tyrosine kinases (Trks) to mediate DRG 
axonal guidance and nerve innervation into peripheral target tissues105, 106.  Trk (A, 
B, and C) receptor stimulation leads to the activation of multiple downstream 
signaling pathways including PLCγ-catalyzed hydrolysis of PIP2105.  It is therefore 
reasonable to speculate that deletion of Pip5k1c could reduce PIP2-mediated Trk 
signaling during developmental stages of axonal outgrowth and innervation, further 
contributing to the reductions in nerve innervation observed in Pip5k1cfl/fl mice.  In 
fact, deletion of TrkA or NGF in mice dramatically reduces innervation into the 
epidermis, similar to the reductions in innervation observed in Pip5k1cfl/fl mice106.  
However, elimination of TrkA or NGF results in a loss of small diameter neurons, a 
phenotype not observed in Pip5k1cfl/fl mice.  A less severe phenotype in Pip5k1cfl/fl 
mice (similar innervation phenotype but lack of cell death) compared to deletion of 
the entire receptor suggests a more subtle mechanism may be responsible for the 
phenotypes such as reduced receptor activity as a result of decreases in PIP2 levels.  
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Further experiments such as calcium imaging using neurotrophin stimulation, as well 
as investigations of actin and tubulin dynamics, are needed to determine exactly 
which mechanism(s) underlie the PIP5K1C-mediated innervation phenotype.  In 
addition, more in-depth immunohistochemical analysis of other tissues is needed to 
fully understand the extent to which innervation is reduced.  
 
Moving forward: Alternatives for conditional Pip5k1c deletion 
 Although conditional homozygous deletion of Pip5k1c produces a 
proprioceptive phenotype, conditional heterozygotes do not display this phenotype, 
rendering them useful for experiments to test our hypothesis that PIP5K1C-mediated 
reductions in nociceptive sensitization are due to specific reductions in the DRG.  
This research is still ongoing; conditional heterozygotes are being bred for 
behavioral and calcium imaging experiments in an effort to recapitulate our findings 
with global heterozygous knockout mice (Chapter II).  Although Advillin is expressed 
in the majority of DRG neurons, a small subset of neurons that do not express 
Advillin may account for the 25% of PIP5K1C protein still detected in Pip5k1cfl/fl 
mice100.  If Advillin-driven Cre reduces PIP5K1C protein expression by at least 40% 
(the level observed in the DRG of global Pip5k1c+/- mice) in the heterozygous 
conditional mice, we will be able to use the conditional heterozygotes to test our 
hypothesis. 
 Additionally, there are other options for conditionally deleting Pip5k1c in 
sensory neurons only.  For example, we can focus our efforts on specific subtypes of 
DRG neurons such as TRPV1- or sodium channel Nav1.8-expressing neurons, as 
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TRPV1- and Nav1.8-driven Cre recombinase lines have been well characterized107, 
108.  Given the modest TRPV1-mediated phenotype in Pip5k1c+/- mice and the 
expression profile of Nav1.8, Nav1.8-driven Cre would be the best option.  Nav1.8 is 
expressed in virtually all small-diameter nociceptive neurons but is absent in large-
diameter DRG neurons and CNS tissue107.  The lack of expression in large-diameter 
neurons may prevent the development of the proprioceptive phenotype. 
 Another option for conditional deletion of PIP5K1C, and one that would be 
most likely to prevent the proprioceptive phenotype, would be an inducible Cre 
recombinase line.  Several such lines exist including an inducible Advillin-driven Cre 
known as Advillin-Cre-ERT2.  This line expresses Cre fused to a mutated ligand-
binding domain from the human estrogen receptor (Cre-ERT2) which is driven by the 
Advillin promoter and only activated following administration of the synthetic 
estrogen receptor agonist, tamoxifen109.  Use of the Advillin-driven inducible Cre 
recombinase system would allow for conditional deletion of Pip5k1c in adult sensory 
neurons only, and would likely prevent the proprioceptive phenotype that is likely 
due to defects in axonal outgrowth and innervation during development. 
  
  
74 
Figures 
 
 
 
 
 
 
 
 
Figure 3.1.  Intrathecal PIP2 injections selectively increase PIP2 in the DRG.   
(A-B) Intrathecal injections of 0.3nmol carrier + 0.3 nmol PIP2 elevate PIP2 levels in 
(A) lumbar DRG but not in (B) lumbar spinal cord.  Significant increases in PIP2 
levels are observed at 1 and 2 hours post injection.  PIP2 was quantified using a 
competitive binding mass ELISA specific for PI(4,5)P2.  n=5 WT mice per time point. 
**p<0.005, ***p<0.0005. Data are presented as mean ± SEM.  
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Figure 3.2.  Generation of Pip5k1cfl/fl conditional knockout mice.   
Diagram of the wild-type Pip5k1c allele and targeting construct.  The neomycin 
cassette and LacZ reporter are removed using the FRT-FLP system.  Mice 
expressing Cre driven by the Advillin promoter are used to delete Pip5k1c (Exon 5 
flanked by LoxP sites) in sensory neurons only. 
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Figure 3.3.  Pip5k1c is selectively eliminated in sensory neurons of the DRG. 
(A-D) Pip5k1c in situ hybridization in (A, B) lumbar DRG and (C, D) lumbar spinal 
cord (superficial dorsal horn) from wt/wt controls and Pip5k1cfl/fl mice.  Scale bar, 50 
µm.  (E, F) PIP5K1C protein levels in adult DRG of male Pip5k1c+/+ and Pip5k1c+/- 
mice relative to β-actin.  (E) Western blots and (F) quantification; n=3 per genotype.  
Data are presented as mean ± SEM. *p<0.05 by unpaired t test. 
 
  
77 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.  Sensory-neuron specific deletion of Pip5k1c produces a 
proprioceptive phenotype.   
(A) Images showing the difference in leg position between wt/wt controls and 
Pip5k1cfl/fl mice when held by the tail.  (B) Image showing the extended hindlimb 
position exhibited by Pip5k1cfl/fl mice.  (C) (B,C) Gait analysis with adult wt/wt and 
Pip5k1cfl/fl mice.  Five stride and five stance measurements per animal.  n=3 male 
mice per genotype.  Data are presented as mean ± SEM. 
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Figure 3.5 Sensory-neuron specific deletion of Pip5k1c reduces nerve 
innervation into the skin.   
(A,B) PGP9.5 (nerve innervations; green) and DRA!5 (nuclei marker; blue) staining 
of glabrous hindpaw skin from (A) wt/wt and (B) Pip5k1cfl/fl mice.  (C, D) PGP9.5 and 
  
79 
DRAQ5 staining of the hindpaw volar pad from (C) wt/wt and (D) Pip5k1cfl/fl mice.  
(E, F) PGP9.5 and DRAQ5 staining of hairy hindpaw skin from (E) wt/wt and (F) 
Pip5k1cfl/fl mice. 
 
  
CHAPTER IV 
 
DEVELOPMENT OF A HIGH-THROUGHPUT SCREENING ASSAY IDENTIFIES A 
SMALL MOLECULE INHIBITOR OF PIP5K1C THAT ATTENUATES 
NOCICEPTIVE SIGNALING AND SENSITIZATION 
 
Introduction 
A large majority of phosphatidylinositol (PI) lipids contribute to tight regulation 
of cellular processes including migration, vesicle trafficking, endocytosis, exocytosis, 
proliferation, and survival 110-113.  However, because the role of phosphatidylinositol 
3-kinases (PI3Ks) in cancer proliferation and survival has been extensively 
characterized, the vast majority of lipid kinase drug discovery efforts over the past 20 
years (starting with the discovery of the first PI3K inhibitor, wortmannin) have been 
directed towards PI3Ks with relatively little investigation into other lipid kinase 
families.  With more recent studies focused on the validation of additional lipid 
kinase families in disease pathophysiology such as of sphinogsine 1-kinase in 
cancer proliferation114, 115, phosphatidylinositol 5-phosphate 4-kinase (PIP4K2) in 
insulin signaling116, and phosphatidylinositol 4-phsphate 5 kinase (PIP5K1C) in pain 
(Chapter II), there is renewed excitement around the development 
of high-throughput screening assays to identify inhibitors of these lipid kinases to 
promote a better understanding of the associated disease states.   
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Phosphatidylinositol 4,5-bisphosphate (PIP2), one of the most abundant 
phosphoinositides produced by the complex PI pathway, tightly regulates a multitude 
of cellular processes including G-protein-coupled receptor signaling, endocytosis, 
exocytosis, cytoskeletal dynamics, and vesicle trafficking 45, 65, 67.  Type I PIP kinases 
(PIP5K1s) and type II PIP kinases (PIP4K2s) synthesize PI(4,5)P2 from 
phosphatidylinositol monophosphates (PIPs), PI(4)P and PI(5)P, respectively.  Davis 
and colleagues developed a high-throughput assay to identify inhibitors of PIP4K2B 
that could advance the field of lipid kinase regulation of insulin signaling117.  
Similarly, we aimed to develop a high throughput screen (HTS) to identify small 
molecule inhibitors that could be used to further validate PIP5K1C as a therapeutic 
target in chronic pain.   
Current assays to monitor PIP5K1-dependent PIP2 synthesis include the use 
of lengthy lipid extraction protocols, radiolabeled ATP, and thin layer 
chromatography, which are not easily amenable to high throughput screening46, 51.  
Due to previous limitations in assay development, there are currently no reported 
inhibitors of PIP5K1s.  Thus, we sought to develop our high-throughput screening 
(HTS) assay using fluorescently conjugated PI(4)P, the natural substrate for 
PIP5K1C, and full length recombinant PIP5K1C that would eliminate the use of 
radiolabeled ATP and lengthy lipid extraction and micelle preparation protocols.  As 
such, we report the first high-throughput assay for PIP5K1 activity.  In addition, we 
used the assay to identify a potent (IC50~40 nM) and selective PIP5K1C inhibitor, 
UNC3230 (previously referred to as UNC1 in abstract), which attenuates pain 
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signaling and sensitization in a manner similar to Pip5k1c haploinsufficiency 
(Chapter II). 
 
Methods 
Materials 
Fluorescein conjugated phosphatidylinositol 4-phosphate [PI(4)P, 9000655] 
and fluorescein conjugated phosphatidylinositol 4,5-bisphosphate (PIP2, 10010388) 
were purchased from Cayman Chemical and reconstituted in 100% DMSO to 1.5 
mM.  N-terminal His6-tagged full length (90 kDa) recombinant human PIP5K1C was 
purchased from Millipore (14-845M).  ProfilerPro separation buffer (760367) and 
coating-reagent 8 (CR-8; 760278) were purchased from PerkinElmer.  PIP5K1C 
enzyme solution is used at a final concentration of 3 nM in assay buffer (Table 1) 
containing 0.01% BSA, 1mM DTT, 1x protease inhibitors (Roche mini complete 
tablets), and 1x phosphatase inhibitors.  PI(4)P substrate solution is used at a final 
concentration of 1 µM in assay buffer containing 0.05% DMSO and 15 µM ATP (Km 
for PIP5K1C). 
 
Animals 
All procedures involving vertebrate animals were approved by the Institutional 
Animal Care and Use Committee at the University of North Carolina at Chapel Hill.  
Wild-type (WT) C57Bl/6 mice were purchased from Jackson Laboratories (#000664) 
or bred in-house. 
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LOPAC Library 
The library of pharmacologically active compounds (LOPAC) library was 
purchased from Sigma and used as an assay validation library.  The 1280 
compounds were supplied as 1-uL samples (10 mM) in 384-well polypropylene 
microplates (Grenier).  On the day of screening, plates were thawed and diluted 
(1:100) to 0.1 mM (1000x the final assay concentration) with assay buffer (Table 1) 
in the 384-well plate.  The Multidrop was used to add 100 µL of 1% DMSO to 
columns 1,2, 23, and 24 which did not contain compound and serve as control 
columns.  A Multimek NSX-1536 assay workstation system fitted with a 384-well 
head (Nanoscreen, Charleston, SC) was used to transfer 2 µL of each sample into 
384-well ShallowWell Nunc assay plates (ThermoScientific, 267459). 
 
Kinase-focused Library  
The 4,727 compound kinase-focused library was prepared and generously 
provided by the UNC Center for Integrative Chemical Biology and Drug Discovery 
(CICBDD)118.  On the day of screening, plates were prepared as described for the 
LOPAC library. 
 
Screening 
A Multidrop Combi Reagent Dispenser was used for the addition of all 
reagents to assay plates.  First 10 µL of 90 mM EDTA (in assay buffer) was added to 
each well in columns 1 and 2 and serve as negative control reactions.  Nine 
microliters of 2x enzyme solution was added to each well of the entire plate.  Plates 
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were incubated at room temperature for 10 minutes then 9 µL of 2x substrate 
solution was added to each well of the entire plate.  Assay plates were incubated in 
the dark for 40 minutes at room temperature.  Ten microliters of 90mM EDTA (in 
assay buffer) was then added to columns 3-24 to stop the reactions.  Fluorescently 
conjugated substrate, PI(4)P, and product, PIP2, were detected using the LabChip 
EZ Reader II microfluidic mobility shift assay (MSA) platform from PerkinElmer.  
ProfilerPro separation buffer containing 1.5% CR-8 was used.  Separation 
conditions: -2000 V downstream voltage, -500 V upstream voltage, -2.0 psi 
pressure, post-sample sip time of 120 seconds, final delay of 120 seconds. 
 For dose response curves, compounds were plated as 3-fold serial dilutions 
starting with a top concentration of 10 mM.  The lowest concentration tested in the 
10-point dose response was 0.0005 mM.  Dose response compound plates were 
prepared using a Tecan Genesis200 (Research Triangle Park, NC).  Dose response 
plates were heat-sealed and stored at -20°C until day of use.  On the day of use, 
plates were prepared as described the LOPAC library (see above).  The final top 
concentration was 10 µM. 
 
Data analysis 
Screening data was analyzed using Screenable software (Screenable 
Solutions, Chapel Hill, NC).  Screenable was used to calculate the mean of the 
positive and negative controls, the percent inhibition (with respect to on-plate 
controls) for each reaction and the common assay performance measure, z’, for 
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each plate.  𝑧! = !!!"# !  !!!"#!!"#!!!"#  where max is the negative control (no compound; 
no inhibition) and min is the positive control (+90 mM EDTA; 100% inhibition).  A 
z’>0.5 was considered acceptable for the plate to be included in the overall data 
analysis.  The LabChip software calculated percent conversion for each reaction.  
Compounds from the kinase library were considered hits if they inhibited 
PIP5K1C at ≥80%.  The 80% threshold was determined as greater than 3 standard 
deviations from the mean percent inhibition for the entire screen.  Mean inhibition 
was 14% with a standard deviation of 21%.  Dose response curves were calculated 
using Screenable Software by converting the % conversion to % inhibition with 
respect to on-plate controls and using a 3 or 4-parameter curve fit.  Dose responses 
for kinases tested at DiscoveRx for selectivity were calculated (after normalization to 
the positive control—no inhibition) using GraphPad Prism software and a 4 
parameter curve fit with variable slope. 
 
Selectivity screening 
Two different assays were used to assess selectivity.  ProfilerPro 
(PerkinElmer) was used to assess selectivity of UNC3230 on 48 kinases.  For the 
ProfilerPro assay, UNC3230 was added to reaction-ready (384-well) assay plates 
(PerkinElmer) containing each of the 48 kinases in duplicate and incubated for 15 
minutes.  Matching fluorescent substrates for each kinase (also provided in reaction-
ready 384-well plates) and ATP at the Km for each kinase were added then the plate 
was incubated for 90 minutes.  Fluorescent substrates and products were separated 
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and quantified using the LabChip EZ Reader II microfluidic mobility-shift assay 
(PerkinElmer).  Data for this assay are reported as percent of control (product 
produced in the absence of UNC3230). 
The DiscoveRx KINOMEscan competitive binding assay was used to 
quantitatively measure interactions between UNC3230 and 100 different kinases.  
Briefly, UNC3230 and each DNA-tagged kinase were added simultaneously to 384-
well plates containing immobilized ligands for each of the 100 kinases tested.  Plates 
were incubated for 1 hour and the amount of kinase bound to the immobilized ligand 
was quantified using quantitative PCR and the associated DNA tag.  Binding 
interactions were determined by the amount of kinase that bound to the immobilized 
ligand.  Competitive interactions between the kinase and UNC3230 would prevent 
binding of the kinase to the immobilized ligand.  Data for this assay are reported as 
percent of control (binding of a control compound to the kinase). 
 
Neuron culture 
All DRG were dissected from 3-8 week old male mice following decapitation.  
Neurons were dissociated with manual trituration using a fire polished Pasteur 
pipette in a solution of 2 mg/mL collagenase (Worthington, CLS1) and 5 mg/mL 
dispase (Gibco, 17105-041).  Neurons were cultured with Neurobasal A medium 
(Gibco, 10888) supplemented with 2% B27 (Gibco, 17504), 2 mM L-glutamine 
(Gibco, 25030), 1% penicillin/streptomycin (Gibco, 15140), 50 ng/mL glial derived 
neurotrophic factor (GDNF; Millipore, GF030) and 25 ng/mL nerve growth factor 
(NGF; Millipore, 01-125) in the absence of serum.  Neurons were plated onto 
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coverslips coated with 1 mg/mL poly-D-lysine (Sigma, P7886) and 10 µg/mL laminin 
(Sigma, L2020) and cultured for 18-24 hours prior to use. 
 
Immunocytochemistry 
Biotinylated PIP2 primary antibody was purchased from Echelon Biosciences 
(Z-B045) and used according to the manufacturer’s instructions.  All PIP2 staining 
was completed at 37°C with Tris-buffered saline (50 mM Tris and 150 mM NaCl at 
pH 7.4).  Chicken anti-NeuN (1:250; Aves) was added to the primary incubation.  
Alexa-conjugated streptavidin (1:2000; Invitrogen) and fluorescently labeled anti-
chicken antibodies (1:1000;Invitrogen) were used for secondary detection. 
 
Calcium imaging 
Calcium imaging of dissociated neurons was completed as described 
previously using Fura 2-acetoxymethyl ester (2 µM; F1221, Invitrogen)73.  Briefly, 
neurons were incubated with 2 µM Fura 2-AM for 60’ followed by 30’ incubation with 
Hanks buffered saline solution (HBSS) prior to carrier/PIP2 incubation.  Neurons 
were then incubated with either carrier alone (2 µM; Echelon Biosciences, P-9C2) or 
carrier + PIP2 (2 µM; Echelon Biosciences, P-4516) for 15 minutes prior to imaging.  
Carrier and PIP2 complexes were formed by incubating together in HBSS at room 
temperature for 15 minutes prior to use.  LPA (10 µM; Avanti Polar Lipids, 857130) 
and KCl (100 mM; Fisher P330) were used for neuron stimulation. 
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Behavioral Assays 
Thermal sensitivity was measured using a Plantar Test apparatus (IITC) to 
heat each hindpaw and the latency for hindpaw removal was recorded.  One 
measurement was taken for each hindpaw to determine the withdrawal latency in 
seconds.  The radiant heat source intensity was calibrated so that the average 
withdrawal latency for WT mice was ~10 s.  Cut off time was 20 s.  Mechanical 
sensitivity was measured using an electronic von Frey apparatus (IITC) and a semi-
flexible tip.  Three measurements for each hindpaw were taken and averaged to 
determine the withdrawal threshold in grams.  Inflammatory (CFA) and neuropathic 
(LPA) models of chronic pain were performed as described previously71, 77, 78.  
Intrathecal injections (5 µL) were performed in unanaesthetized mice using the direct 
lumbar puncture method 81.  UNC3230 was prepared at a 0.4 mM (2 nmol in 5 µL) in 
20% DMSO (in saline). 
 
Results 
Assay design and development 
Prior to the development of this assay, standard methods to monitor PIP5K1 
activity included the use of radiolabeled ATP, thin layer chromatography, and 
lengthy lipid extraction protocols46, 51.  To avoid lengthy lipid extraction protocols 
required when using eukaryotic cell lysates, we decided to use recombinant 
PIP5K1C and a fluorescein conjugated PI(4)P substrate in a strictly in vitro reaction 
(Figure 4.1A).  Although there are no reported assays that monitor PIP2 from any of 
the three natural substrates, there was an assay recently developed that used the 
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PerkinElmer LabChip microfluidic mobility shift assay (MSA) to monitor the 
phosphorylation of PIP2 to phosphatidylinositol 3,4,5-triphosphate (PIP3) by PI3K119.  
Using the reported PI3K assay buffer and the PerkinElmer LabChip MSA, we were 
able to observe baseline separation of 1 µM fluorescein-conjugated PIP2 and 1 µM 
fluorescein conjugated PI(4)P (both purchased from Cayman chemical and prepared 
in assay buffer) using ProfilerPro separation buffer with 1.5% coating reagent 8 (CR-
8) (Figure 4.1B; Table 4.1).  Notably, the presence of sodium cholate in the assay 
buffer is imperative to achieve separation and prevent aggregation of lipids (data not 
shown).  The proprietary CR-8 allows for run-to-run separation consistency and 
prevents aggregation and adsorption of the substrate and kinase to the 
microchannel surfaces120.  Baseline separation of the substrate and product 
indicated that the LabChip MSA would be suitable for continued assay development. 
Fluorescein conjugated PI(4)P (1 µM) was incubated with 100 µM full length 
(668 amino acid; 90 kDa) recombinant human PIP5K1C and varying concentrations 
of adenosine triphosphate (ATP; three fold serial dilution starting at 1000 µM) to 
determine the ATP Km.  The LabChip MSA was used to monitor the reactions 
kinetically (every 5 minutes for ~80 minutes) and Michaelis-Menten analysis 
revealed an ATP Km of 15 µM (Figure 4.2A, 4.2B, and Table 4.1).  Next, reactions 
containing 1 µM PI(4), 15 µM ATP, and varying concentrations (two-fold serial 
dilution starting at 10 nM; 7 concentrations total) of PIP5K1C were read kinetically 
(every 6 minute for 45 minutes) to determine the concentration of enzyme that would 
give ~30% conversion of substrate to product at an end-point within the linear range 
of the reaction.  A final concentration of 3 nM PIP5K1C and a 40-minute incubation 
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time were chosen (Figure 4.2C and Table 4.1).  Kinase titrations were preformed for 
every vial of enzyme purchased over the course of assay development to account 
for slight differences in kinase activity from lot to lot.  
 Given that compound libraries are dissolved in 100% DMSO, reactions 
containing 1 µM PI (4), 15 µM ATP, 3 nM PIP5K1C, and varying concentrations of 
DMSO (two-fold serial dilutions starting at 10%; 9 concentrations total) were 
performed to determine DMSO tolerance after 40 minute reactions (Figure 4.2D).  
There was decreased activity in reactions containing >1% DMSO indicating the final 
concentration of DMSO within the reaction must be lower than 1% (Figure 4.2D).  
Compounds are prepared as 10 mM stocks in 100% DMSO then diluted to a final 
concentration of 10 µM (1:1,000) and 0.1% DMSO which is well within the DMSO 
tolerability of the reaction.  Finalized reactions containing 1 µM PI(4), 15 µM ATP, 3 
nM PIP5K1C, and 0.1% DMSO produce the envisioned 30% conversion of substrate 
to product following a 40 minute incubation, indicating completion of the assay 
design stage (Figure 4.2E).   
 Next, we transitioned this assay into a high-throughput screening format 
which began with automation validation using a Multidrop Combi Reagent Dispenser 
for delivery of the enzyme and substrate solutions.  We initially observed 
inconsistent delivery of lipid substrate and kinase to the plate, most likely due to lipid 
adsorption to the silicone tubing of the Multidrop delivery cassette121.  To overcome 
adsorption problems, a final concentration of 0.01% BSA and 0.05% DMSO were 
included in the enzyme and substrate solutions, respectively, to serve as carriers 
and mitigate adsorption122 (Table 4.1).  In addition, the silicone lines of the multidrop 
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delivery cassette were primed with 5 mL of 0.02% BSA prior to kinase dispensing 
and 5 mL of 1% DMSO prior to substrate dispensing.  Addition of BSA and DMSO to 
the enzyme and substrate solutions, respectively, allowed for consistent delivery of 
both solutions to multiple plates (data not shown).  Incorporating these changes, 
automation validation was completed over three days and all plates had coefficients 
of variation less than 10%. 
 
Assay validation 
Following automation validation, HTS validation was completed using the 
Nanoscreen MultiMek to transfer 1% DMSO (mimics compound delivery) to each 
assay plate followed by Multidrop delivery of the enzyme and substrate solutions.  
During this stage we confirmed the plate layout for the assay in which negative 
controls (+90 mM EDTA in assay buffer; 100% inhibition) would occupy columns 1 
and 2 while positive controls (no compound; no inhibition) would occupy columns 23 
and 24.  All plates were run in this manner for HTS validation and screening.  HTS 
validation was carried out over three days, 2 plates per day.  HTS validation 
revealed excellent assay performance with Z’ values above 0.9 on all three days 
(Figure 4.3A).  We then used the library of pharmacologically active compounds 
(LOPAC) as a validation library to examine reproducibility of our assay.  The 1280 
LOPAC compounds were run in duplicate over two days (4 plates per day).  The 
assay was deemed excellent with respect to Z’ in which all plates ranged from 0.7 to 
0.9 (Figure 4.3A).  The data fit with a linear regression line revealed an r2 and slope 
of 0.966, indicating a highly reproducible assay (Figure 4.3B).  
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Screening 
A kinase-focused library of 4,727 compounds that was designed and made 
available by the UNC Center for Integrative Chemical Biology and Drug Discovery 
(CICBDD) was screened at 10 µM in 0.1% DMSO118.  Results from the kinase-
focused library were found to follow a normal distribution (Figure 4.4A and 4.4B).  All 
16 plates of the kinase library had a Z’ well over 0.5 with an average Z’ of 0.862 
(Figure 4.4C).  Compounds that exhibited inhibition greater than three standard 
deviations from the mean value were considered active (>80% inhibition; mean of 
14% and standard deviation of 21%).  There were 22 compounds that exhibited 
>80% inhibition of PIP5K1C and were considered active (hit rate of 0.42%; Table 
4.2).  Primary hits were subjected to a set of structure- and property-based filters in 
order to remove the compounds whose physical properties would prevent them to 
penetrate through the cell membrane or induce substantial cellular toxicity.  We 
made use of a softened version of the Lipinski rule123 (2+ violations of Number of H-
bond donors < 6, Number of H-bond acceptors < 12, Molecular Weight between 200 
and 600, ALogP < 5.5) and REOS124. Likewise, we removed compounds featuring at 
least one reactive or toxicity-implicated substructure.  After filtering, 20 compounds 
remained, all of which were classified as singletons (3 or more compounds with 
similar structures are considered clusters) (Table 4.2).   
 
Hit confirmation and follow up of select inhibitors 
All available active compounds were re-tested in 10-point dose response 
curves (in triplicate) to confirm activity and provide potency information (Table 4.2).  
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Compound 20 was unavailable at the time of potency testing (Table 4.2).  Potency 
values were obtained for 18 of the 19 compounds tested, revealing an overall 90% 
confirmation rate for our active compounds.  In addition to active compounds from 
the kinase library, there were 6 active compounds (inhibition >80%; after drug-
likeness filtering) in the LOPAC library; however, the LOPAC library was utilized as a 
validation library and potency information was not obtained for these literature 
compounds (Table 4.3).   
Of the 20 active kinase-focused library compounds, compounds 1 (UNC3230) 
and 2 had identical thiazole carboxamide core structures and were the most potent 
inhibitors of PIP5K1C (IC50 of 0.130 and 0.120 µM, respectively; Figure 4.5A, 4.5B, 
and Table 4.2).  Further optimization of the assay (incubation of kinase with 
compound for 20 minutes prior to the addition of kinase), using a new lot of kinase 
and a tighter dose response curve (10 point; 1 µM highest concentration) gave a 
reproducible potency value of ~40 nM for UNC3230 (Figure 4.6B).  There were 3 
additional compounds with IC50 values less than 1 µM and a total of 7 compounds 
with IC50 values less than 5 µM (Table 4.2).  Based on preliminary secondary 
screening and the nanomolar potency, we continued our focused nociceptive studies 
with UNC3230. 
 
UNC3230 reduces membrane PIP2 levels and reduces pronociceptive receptor 
signaling 
To assess selectivity, we screened UNC3230 against 148 kinases (see 
methods), covering all major branches of the kinome (Figure 4.6C).  Remarkably, 
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UNC3230 inhibited (ProfilerPro assays) or competitively interacted (DiscoveRX 
binding assays) with only five other kinases at our relatively high (10 µM) screening 
concentration (using 10% activity/binding remaining relative to control as the cutoff 
for each kinase group, except lipid kinases, where a more stringent 35% of control 
cutoff was used) (Figure 4.6C, Table 4.4).  Based on dose-responses with the five 
inhibited kinases, UNC3230 showed remarkable selectivity (Kd<0.2 µM; using 
competitive binding assays) for PIP5K1C and PIP4K2C (Phosphatidylinositol-5-
phosphate 4-kinase, type II, gamma) (Figure 4.6D-F).  PIP5K1C and PIP4K2C 
directly generate PIP2, albeit using different substrates; PI(4)P versus PI(5)P, 
respectively.  Importantly, UNC3230 represents the first reported inhibitor for these 
lipid kinases.  
 Inhibition of PIP5K1C and/or PIP4K2C would be predicted to reduce PIP2 
levels, so we assessed how UNC3230 affected PIP2 levels in DRG neurons using 
the PIP2-specific antibody (described in Chapter II).  We found that membrane PIP2 
levels were significantly reduced by ~45% in DRG neurons treated with 100 nM 
UNC3230 (~2-fold IC50) relative to vehicle controls (Figure 4.7A and 4.7B).  In 
addition, we found that UNC3230 significantly reduced LPA-evoked calcium 
signaling in cultured DRG neurons relative to vehicle (Figure 4.7C and 4.7D).  KCl-
evoked calcium release was not reduced indicating cell health is not contributing to 
the observed signaling deficits.  Collectively, our data indicate that UNC3230 
represents a novel pharmacological probe that can be used to inhibit two lipid 
kinases that directly generate PIP2.  Moreover, our data suggest that UNC3230 
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blunts pronociceptive receptor signaling in DRG neurons in a manner that is 
analogous to Pip5k1c haploinsufficiency (Chapter II).   
 
UNC3230 has antinociceptive effects when injected intrathecally 
We monitored acute thermal and mechanical sensitivity in WT mice before 
and shortly after i.t. administration of 2 nmol UNC3230 (limited solubility in a number 
of vehicle formulations prevented us from testing higher doses, data not shown).  
We found that paw withdrawal latency in response to radiant heating of the hindpaw 
was significantly increased one and two hours after i.t. injection of UNC3230 
compared to controls (Figure 4.8A).  In contrast, no acute effects on mechanical 
sensitivity were observed following UNC3230 administration (Figure 4.8B).  Given 
that UNC3230 blunted LPA-evoked signaling, and that LPA enduringly enhances 
thermal and mechanical sensitivity by activating LPA receptors over a brief three 
hour critical period78, we next evaluated the extent to which UNC3230 could reduce 
LPA-evoked thermal and mechanical hypersensitivity.  We administered UNC3230 
(2 nmol; i.t.; versus vehicle) then 1 hour later co-injected 1 nmol LPA with UNC3230 
(2 nmol, i.t.; versus vehicle).  UNC3230 significantly blunted thermal hyperalgesia 
and mechanical allodynia compared to vehicle (Figure 4.8C and 4.8D).  Next, we 
administered UNC3230 (2 nmol; i.t.) 2 hours before and 2 hours after injecting CFA 
into one hindpaw.  We found that UNC3230 significantly blunted thermal 
hyperalgesia and mechanical allodynia in the CFA-inflamed hindpaw (relative to 
vehicle control) but did not affect thermal or mechanical sensitivity in the control 
(non-inflamed) hindpaw over a multiday time course (Figure 4.8E and 4.8F).  Taken 
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together, these data reveal that UNC3230 has acute thermal antinociceptive effects 
in uninjured mice and can attenuate thermal and mechanical hypersensitivity when 
administered prior to the onset of LPA-evoked neuropathic pain and CFA-evoked 
inflammatory pain.   
 
Discussion 
Investigation of PIP5K1C regulation of cellular processes and disease 
physiology has been restricted to genetic approaches to reduce kinase activity due 
to the lack of reported inhibitors.  Current studies have utilized genetic deletion of 
PIP5K1C using knockout mice, targeted small interfering RNA (siRNA) and shRNA, 
and kinase assays that require lengthy lipid extraction protocols and radiolabeled 
ATP 45, 46, 51, 113.  Unfortunately these kinase assays have not been amenable to high 
throughput screening, preventing the identification of PIP5K1C inhibitors.  Moreover, 
the use of PIP5K1C genetic knockout mice is time- and resource-intensive and limits 
studies to chronic deletion of the enzyme, thwarting information on acute inhibition of 
just the catalytic activity125.  Here, we report the successful development of a high-
throughput assay for PIP5K1C activity, screening of a kinase-focused library to 
identify inhibitors of PIP5K1C, and characterization of the most potent compound, 
UNC3230 in nociceptive signaling and sensitization. 
 
 
 
  
97 
UNC3230 is a potent and selective inhibitor of UNC3230 that has activity 
similar to Pip5k1c haploinsufficiency 
UNC3230 has an in vitro IC50 of approximately 40 nM and shows remarkable 
selectivity when assayed against 148 kinases that cover each branch of the kinome.  
For the 100 kinases screened using the DiscoveRx platform, the DiscoveRx 
Selectivity Profile score for UNC3230 was 0.12 (on a scale from 0 to 1.0)126.  To put 
this value in context, of 38 kinase inhibitors (several of them FDA-approved) 
benchmarked in this assay at 3 µM 126, a majority (n=22) were less selective than 
UNC3230.  The only other kinase UNC3230 inhibited with equal or greater potency 
was PIP4K2C, another enzyme that synthesizes PI(4,5)P2.  In contrast to PIP5K1C, 
PIP4K2C phosphorylates PI(5)P which is at least 10x less abundant than PI(4)P67, 
111.  Given that PI(4)P is at much higher concentrations, the ~50% reduction in PIP2 
in DRG neurons following incubation with UNC3230 is most likely due to inhibition of 
PIP5K1C rather than PIP4K2C.  Notably, UNC3230 did not interact with PIP5K1A at 
10 µM, a PIP5K family member that is highly similar (69% amino acid identity across 
the entire protein and 82% identity within the kinase core domain) to PIP5K1C 
(Figure 4.9) Moreover, UNC3230 did not inhibit any of the other lipid kinases that 
regulate phosphoinositide levels, including phosphatidylinositol-4,5-bisphosphate 3-
kinases (PIK3s, also known as PI3Ks) (Table 4.4).  Note, PIP4K2C should not be 
confused with phosphatidylinositol 4-kinases (PI4Ks) that generate PI(4)P from 
phosphatidylinositol and that can be inhibited by wortmannin and phenylarsine oxide 
(PAO; Figure 4.9)127.        
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The most important finding of this Chapter is that PIP5K1C pharmacological 
inhibition with a small molecule reduces pronociceptive signaling analogous to 
reductions observed in the Pip5k1c haploinsufficiency model (Chapter II).  This 
indicates that reduction of catalytic activity in adult neurons is sufficient for reducing 
the activity of pronociceptive receptors.  Importantly, intrathecal injection of 
UNC3230 has antinociceptive effects in response to thermal stimuli.  Furthermore, 
administration of UNC3230 just prior to induction of LPA-induced neuropathic pain or 
CFA-induced inflammatory pain (and a second co-injection with LPA and second 
injection 2 hour following CFA administration) attenuates nociceptive sensitization.  It 
is worth noting that reductions in nociceptive sensitization following nerve injury and 
inflammation were less pronounced following UNC3230 administration compared to 
reductions observed in the Pip5k1c haploinsufficiency model, particularly reductions 
in mechanical sensitivity.  This could be due to other phenotypes that were observed 
in the Pip5k1c haploinsufficiency model such as alterations to actin and tubulin 
dynamics that have yet to be evaluated following UNC3230 treatment.  Likewise 
differing phenotypes may arise from chronic inhibition of catalytic activity and/or 
deletion of the PIP5K1C protein in the haploinsufficiency model that are not present 
following acute inhibition with a small molecule (Chapter II).  To evaluate differences 
between acute and chronic inhibition (Chapter II), additional experiments are needed 
including evaluation of actin and tubulin dynamics, TRPV1-mediated calcium 
imaging, and ion channel-mediated neuronal excitability in DRG neurons incubated 
with UNC3230.  These experiments will allow for more in-depth comparison between 
pharmacological inhibition and genetic deletion.  Furthermore, in order to make 
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reliable assessments of differences/similarities of UNC3230 and Pip5k1c 
haploinsufficiency in models of chronic pain, the models should be performed with 
WT mice receiving vehicle, WT mice receiving UNC3230, and Pip5k1c+/- receiving 
vehicle simultaneously.  Importantly, further characterization of UNC3230 is still 
ongoing, including evaluation of UNC3230’s potential to reduce DRG neuronal 
excitability, the predominant mediator of prolonged pain hypersensitivity.  
 
UNC3230 provides a scaffold for future compound development 
Unfortunately, UNC3230 has aqueous solubility issues that prevented in-
depth analysis of the compound at a wide range of concentrations in vitro and in 
vivo, highlighting the need for medicinal chemistry optimization to increase solubility 
while maintaining or enhancing potency and selectivity.  Unlike the PIP4K2s, there 
are no crystal structures of any of the PIP5K1s making structure-guided drug design 
difficult117; however, standard structure-activity relationship (SAR) studies are 
feasible and ongoing.  Although there are no crystal structures available for 
PIP5K1Cs, it may be possible to generate a homology model using the crystal 
structure of PIP4K2C to aid in drug discovery efforts128, 129.  Unfortunately, the 
sequence homology between PIP4K2C and PIP5K1C is only ~33% which is not 
considered ideal and will most likely prevent obtaining reliable and detailed 
information on UNC3230 interactions with PIP5K1C based on PIP4K2C128, 129.  
Nonetheless, we know that UNC3230 potently inhibits PIP4K2C and not PIP4K2A 
and we may be able to use computational modeling and the known crystal structures 
of PIP4K2A and PIP4K2C to determine possible interaction sites of UNC3230 with 
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PIP4K2C that are different from PIP5K2A and may be similar to PIP5K1C.  The 
developed assay will allow for high-throughput evaluation of analogues derived from 
the identified thiazole carboxamide core structure as well as any other core 
structures identified via additional screening. 
 
Implications for phosphoinositide signaling studies 
Although we describe the characterization of UNC3230 in pain signaling and 
sensitization, studies of UNC3230 in other PIP5K1C-regulated cellular processes 
are needed.  Current techniques in the field of PIP5K1C-regulated cellular processes 
depend on overexpression of phosphatases and kinases that transiently eliminate or 
synthesize PIP2, respectively 113, 130, 131.  The identified inhibitors provide a new tool 
for these studies that eliminates the need for overexpression and allows transient 
inhibition while maintaining physiologically relevant protein levels of the phosphatase 
and kinases in the PI pathway.   
As mentioned previously, many previous studies investigated the roles of 
PIP5K1C have relied on genetic deletion in mice that chronically eliminates the 
kinase which prevents understanding alterations of cellular processes following 
acute inhibition.  Previous attempts to study differences in acute and chronic 
inhibition have relied on overexpression of PIP5K1 constructs containing a kinase 
dead mutation via transient transfection83.  This is not ideal for many cell types 
including our cell type of interest, DRG neurons, due to an inability to transiently 
transfect cells with high efficiency (data not shown).  DRG neurons can be 
transduced using lentiviral vectors; however making kinase dead mutant expression 
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constructs is time-intensive and prevents efforts to evaluate endogenous levels of 
PIP5K1s (data not shown).  UNC3230 can now be used in DRG neurons to 
elucidate which cellular processes are affected by chronic inhibition or non-catalytic 
functions of PIP5K1C.  Moreover, small molecule inhibitors provide a 
complementary pharmacological approach to reinforce findings from previously used 
genetic techniques, as we have demonstrated 125.   
 
High throughput screening assay can be expanded to include other lipid 
kinases 
The developed assay can be extended to the study of other lipid kinases that 
play important roles in cellular signaling and disease pathology.  The only limitation 
to expansion of this assay is availability of fluorescently conjugated substrates and 
recombinant proteins.  However, many fluorescently labeled lipid substrates are 
available for purchase from a variety of vendors and recombinant proteins are 
routinely expressed and purified from bacculovirus and bacterial systems.  
Furthermore, this new assay can be expanded to screen larger-scale libraries such 
as the 100K Diversity compound library (available at the UNC CICBDD) to provide 
additional scaffolds for continued development of PIP5K1C inhibitors for analgesic 
drug development. 
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Tables 
 
Table 4.1.  PIP5K1C HTS microfluidic mobility shift assay conditions. 
 
Assay buffer 50 mM MOPS, pH 6.5, 500 µM sodium cholate, 10 mM 
MgCl2, 25 mM NaCl 
Separation buffer ProfilerPro separation buffer with 1.5% coating reagent 
8 (CR-8)    
Separation conditions -2000 V downstream voltage, -500 V upstream voltage, 
-2.0 psi pressure, post-sample sip time of 120 seconds, 
final delay of 120 seconds. 
Enzyme*  3 nM, prepared in assay buffer with 0.01% BSA (fatty 
acid free), 1 mM DTT, 1x protease inhibitors, 1x 
phosphatase inhibitors 
Substrate 1 µM prepared in assay buffer with 0.05% DMSO and 
15 µM ATP (Km) 
Endpoint assay setup 9 µL 2x enzyme solution added to compound plate (2 
µL in 100% DMSO), incubate 10 minutes, 9 µL 2x 
substrate solution added, incubate 40 minutes, 10µL 
stop solution added 
Incubation 40 minutes at room temperature 
Reaction plate Nunc shallow 384 well 
Stop solution 90 mM EDTA, pH 8.0 in assay buffer 
*Enzyme concentration is lot specific and must be titrated for each lot 
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Table 4.2.  Active compounds from the kinase-focused library. 
 
 
Active compound that passed drug-likeness filtering (22): 
 
 
Compound # 
 
Molecule 
Inhibition (%) 
at 10 µM 
(initial 
screen) 
IC50 (µM; 
mean ± SD) 
 
 
 
1 
  
 
 
94 
 
 
 
0.12 ± 0.03 
2 Not disclosed 93 0.13 ± 0.03 
 
 
 
3 
  
 
 
81 
 
 
 
0.22 ± 0.01 
 
 
 
 
4 
  
 
 
 
81 
 
 
 
 
0.23 ± 0.01 
 
 
5 
  
 
91 
 
 
0.90 ± 0.08 
6 Not discolsed 83 1.2 ± 0.06 
7 Not discolsed 89 2.2 ± 1.0 
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8 
  
 
 
83 
 
 
 
5.1 ± 0.77 
 
 
 
9 
  
 
 
80 
 
 
 
6.1 ± 0.44 
 
 
10 
  
 
83 
 
 
6.2 ± 0.35 
 
 
 
11 
  
 
 
88 
 
 
 
6.5 ± 0.64 
 
 
 
 
12 
  
 
 
 
83 
 
 
 
 
7.3 ± 0.21 
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13 
  
 
80 
 
 
 
7.9 ± 1.2 
 
 
 
 
14 
  
 
 
 
81 
 
 
 
 
9.1 ± 0.56 
 
 
 
15 
  
 
 
101 
 
 
 
 
9.6 ± 0.77 
 
 
 
16 
  
 
 
80 
 
 
 
9.7± 0.31 
 
17 
  
81 
 
10 ± 0 
 
 
 
18 
  
 
 
87 
 
 
 
10 ± 0 
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Active compound that did not pass drug-likeness filtering (2) 
 
 
21 
  
 
81 
 
 
 
Not tested 
 
 
 
 
22 
 
  
 
 
 
 
88 
 
 
 
 
 
Not tested 
 
 
  
 
 
19 
  
 
89 
 
 
Not active 
 
 
20 
  
 
95 
 
 
Not 
available for 
testing 
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Table 4.3.  Active compound from the LOPAC library. 
 
Molecule 
 
Name 
 
Description 
from LOPAC 
library 
Inhibition 
(%) in 
PIP5K1C 
screen 
 Nordihydroguaiaretic 
acid from Larrea 
divaricata 
Lipoxygenase 
inhibitor 
 
96 
 
  
 
 
ARP 101 
A matrix 
metalloprotei
nase 2 
(MMP-2) 
selective 
inhibitor. 
 
 
 
92 
  
 
 
Fluspirilene 
 
Dopamine 
receptor 
antagonist; 
antipsychotic 
 
 
 
90 
  
 
SB 415286 
Competitive 
glycogen 
synthase 
kinase-3 
(GSK-3) 
inhibitor. 
 
 
90 
  
 
BIO 
Potent, 
selective, and 
ATP-
competitive 
GSK3alpha/b
eta inhibitor. 
 
 
89 
  
 
Chelerythrine 
chloride 
 
 
PKC inhibitor 
 
 
89 
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Table 4.4.  Kinases screened for UNC3230 selectivity.  Numbers represent  
% activity/binding remaining in the presence of 10 µM UNC3230. 
AGC   CMGK   TK  
AKT1 92*  CDK16 94  ABL 92* 
AKT2 98*  CDK19 100  ALK 54 
CDC42BPA 98  CDK2 93*  AXL 75 
DMPK 91  CDK3 100  BTK 102* 
GRK1 96  CDK7 85  CSF1R 100 
P70S6K 74*  CDK9 99  EGFR 98 
PDPK1 100  DYRK1A 12  EPHA2 100 
PRKACA 99*  DYRK1B 16  ERBB2 97 
PRKCB 109*  GSK3B 88, 57*  FGFR1 96* 
PRKCD 87  MAPK1 109*  FGFR2 100 
PRKCE 100  MAPK10 5.4  FLT3 90* 
PRKCG 105*  MAPK11 95  FYN 88* 
PRKCZ 94*  MAPK14 88, 130*  INSR 100* 
ROCK2 99*  MAPK3 91*  ITK 94 
RPS6KA5 96*  MAPK8 32  JAK2 70 
RPS6KA3 85  MAPK9 15  JAK3 94 
RPS6KA1 85*  SRPK3 100  KDR 100* 
RPS6KB1 74*     KIT 100 
SGK1 8, 23*  LIPID   LCK 93* 
STK32C 80  PI4KB 67  LYN 97* 
   PIK3C2B 78  MET 75* 
ATYPICAL   PIK3C2G 93  MUSK 100 
ADCK3 35  PIK3CA 77  NTRK1 99 
PDK2 93*  PIK3CB 95  NTRK2 83 
RIOK1 92  PIK3CD 90  NTRK3 89 
TRPM6 67  PIK3CG 82  PDGFRA 81 
   PIP4K2B 100  PDGFRB 100 
CAMK   PIP4K2C 14  PTK2 97 
CAMK2A 98  PIP5K1A 100  PTK2B 99 
CAMK2G 85*  PIP5K1C 7  RET 100 
CAMK4 93*     SRC 95* 
CHEK2 2.7  OTHER   SRMS 81 
CHK1 101*  AAK1 47  SYK 93* 
DCLK1 87  AURKA 76*  TEC 89 
MAPKAPK2 85*  AURKB 91  TIE1 91 
MAPKAPK5 89*  CHUK 82  TYK2 86 
MARK1 89*  IKBKB 100  TYRO3 94 
MARK3 100, 93*  PLK1 73  ZAP70 89 
MKNK1 95  ULK2 79    
MKNK2 46       
MYLK3 46  STE   TLK  
NUAK2 100  MAP2K1 89  ACVR1B 89 
PHKG1 60  MAP2K2 82  BMPR2 80 
PHKG2 88  MAP3K4 93  BRAF 94 
PIM2 82*  MAP4K4 28, 27*  IRAK4 93* 
PRKD1 84  MINK1 35  LIMK1 100 
STK11 100  MYO3A 64  MAP3K9 74 
TSSK1B 76  MYO3B 49  RAF1 91* 
   PAK1 92  TGFBR1 96 
CK1   PAK2 99*    
CSNK1D 6.8, 54*  PAK4 60    
CSNK1G2 28  STK3 100*    
* Screened using the PerkinElmer ProfilerPro assay, all others screened using  
the DiscoveRx KINOMEscan assay. 
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Figures 
 
Figure 4.1.  Recombinant PIP5K1C can be used to generate fluorescein 
conjugated PIP2 from fluorescein conjugated PI(4)P.  
(A)  Schematic representation of the PIP5K1C reaction using fluorescein conjugated 
PI(4)P as the substrate. (B) PerkinElmer LabChip EZ Reader II and microfluidic 
platform can be used to achieve baseline separation of the fluorescein conjugated 
substrate, PI(4)P, and fluorescein conjugated product, PIP2. 
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Figure 4.2.  PIP5K1C assay development to determine kinase concentration, 
ATP Km, and DMSO sensitivity.   
(A) Progression curves for PIP5K1C reacitons with varying concentrations of ATP.  
(B) Michaelis-Menten analysis of initial rates in (A) to determine ATP Km for 
PIP5K1C.  (C) Progression curves for PIP5K1C with varying concentrations of 
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PIP5K1C to determine the optimal kinase concentration to obtain ~30% conversion 
after 40-minute incubation.  (D) Percent conversion of PIP5K1C reactions at various 
DMSO concentrations after 40-minute incubation to determine DMSO sensitivity of 
the reaction.  (E) Final progression curve for reactions containing all optimized 
parameters.  Mean ± SEM.  n=12 reactions. (A-E)  Percent conversion of substrate 
to product is calculated using PerkinElmer EZ Reader II software. 
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Figure 4.3.  Assay validation using the LOPAC library.  
(A) The common assay performance measurement, z’, for 6 plates (over 3 days) of 
HTS validation and 4 plates of the LOPAC library in duplicate (2 days).  (B) 
Duplicate runs (each on a different axis) of the LOPAC library (1280 compounds) to 
assess reproducibility of the developed assay.  Data are presented as % inhibition 
calculated by on-plate controls.   
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Figure 4.4.  HTS of 4,727 compound kinase-focused library.   
(A) PIP5K1C reactions (expressed as % inhibition determined by on-plate controls) 
for each well of the assay including all negative (yellow) and positive controls (red).  
(B) Distribution of compound activity for the kinase-focused library.  The number of 
compounds with a given activity level (% inhibition) are plotted in a frequency 
histogram.  (C) z’ values for each of the 16 plates of the kinase-focused library. 
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Figure 4.5.  The two most potent inhibitors of PIP5K1C have the same core 
structure and nanomolar potency.  
 (A) Compound 1 (also referred to as UNC1 in abstract and UNC3230) and (B) 
Compound 2 two are the two most potent compounds identified and have the same 
thiazole carboxamide core structure with IC50 values of 130 and 120 nM, 
respectively.  Data are presented as mean ± SD. 
 
  
  
115 
 
 
  
116 
Figure 4.6.  UNC3230 is a selective small molecule PIP5K1C inhibitor.   
(A) Representative traces showing substrate and product peak separation in assay 
performed ± UNC3230 (10 µM).  (B) UNC3230 structure and inhibitory 
concentration-50 (IC50) dose-response curve, using LabChip assay.  (C) Selectivity 
of UNC3230 relative to a diverse panel of kinases, using ProfilerPro (48 kinases) 
and KINOMEscan (100 kinases) assays.  Table 1 lists all kinases that were tested.  
Circle size and color reflects percent activity/binding remaining in the presence of 
UNC3230 (10 µM) relative to controls.  Branches without circles denote kinases that 
were not tested.  AGC: Containing PKA, PKG, PKC families; CAMK: 
Calcium/calmodulin-dependent protein kinase; CK1: Casein kinase 1; CMGC: 
Containing CDK, MAPK, GSK3, CLK families; STE: Homologs of yeast Sterile 7, 
Sterile 11, Sterile 20 kinases; TK: Tyrosine kinase; TKL: Tyrosine kinase-like.  Image 
generated using TREEspot™ Software Tool and reprinted with permission from 
KINOMEscan®, a division of DiscoveRx Corporation, © DISCOVERX 
CORPORATION 2010.  (D-F) KINOMEscan competitive binding assays with multiple 
doses of UNC3230, presented from (D) strongest Kd to (F) weakest Kd.  All data are 
mean ± SEM.  
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Figure 4.7.  UNC3230 reduces membrane PIP2 levels in DRG neurons and 
GPCR signaling.   
(A) PIP2 antibody staining of WT DRG neurons after incubating with vehicle (0.002% 
DMSO) or 100 nM UNC3230 for 20 h.  Co-stained with the neuronal marker NeuN 
(blue).  (B) Quantification of the average perimeter (membrane) intensity.  n=30-40 
neurons per condition.  (C) LPA-evoked calcium response in WT DRG neurons after 
incubating with vehicle or the indicated concentrations of UNC3230 for 20 h.  After 
stimulation, cultures were washed with HBSS for 120 s to remove LPA, then 
stimulated for 30 s with 100 mM KCl to confirm neuron identity.  (D) Quantification of 
the LPA-evoked calcium response by measuring the AUC of each responding 
neuron.  Number of neurons quantified is indicated in bar graph.  Data are mean ± 
SEM.  *p<0.005, ***p<0.005.  
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Figure 4.8.  UNC3230 reduces thermal and mechanical sensitization in models 
of chronic pain.   
(A) Thermal and (B) mechanical sensitivity of WT mice after administering vehicle or 
2 nmol UNC3230 (i.t.).  Arrow indicates injection.  n=10 male mice per group.  (C) 
Thermal and (D) mechanical sensitivity of WT mice in the LPA-induced neuropathic 
pain model.  Vehicle or 2 nmol UNC3230 were administered i.t.  One hour later, 
vehicle or 2 nmol UNC3230 was administered i.t. with 1 nmol LPA.  n=10 male mice 
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per group.  (E) Thermal and (F) mechanical sensitivity of WT mice in the CFA model 
of inflammatory pain.  Vehicle or 2 nmol UNC3230 were administered i.t.  Two hours 
later, CFA was injected into one hindpaw of each animal.  The other hindpaw was 
not inflamed and served as a control.  Vehicle or 2 nmol UNC3230 was administered 
(i.t.) 2 hours after CFA injection.  n=10 male mice per group.  (A) Unpaired t-tests 
were used to assess differences at each hour.  (C-F) One-way ANOVAs were used 
to assess treatment effect over the 7-day time course.  All data are mean ± SEM.  
*p<0.05, **p<0.005. 
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Figure 4.9.  Selectivity of UNC3230 relative to lipid kinases that generate 
phosphoinositides.   
Shown are the gene symbols and percent activity/binding remaining in the presence 
of 10 µM UNC3230 (dose-response curves were generated for the kinases shown in 
red; see Figure 4).  Additional lipid kinases generate phosphoinositides (not shown; 
because recombinant versions were not available for testing).  UNC3230 inhibits 
PIP4K2C and PIP5K1C.  These lipid kinases generate PIP2 directly from PI(5)P and 
PI(4)P, respectively.  Wortmannin and phenylarsine oxide (PAO) inhibit lipid kinases 
that generate PI(4)P and PI(3,4,5)P2.  PI = phosphatidylinositol. 
Chapter V 
 
DISCUSSION AND PERSEPCTIVE 
 
Summary and Scope 
 Nociceptive pain is essential for survival, protecting against harmful stimuli 
and promoting avoidance of harmful situations10, 12.  However, peripheral 
sensitization of neurons within the nociceptive system during nerve injury or 
inflammation leads to the development of maladaptive chronic pain4, 6, 10, 12.  Chronic 
pain affects more than 35% of adults in the United States and costs over $600 billion 
to treat annually1, largely due to loss of productivity costs from patients’ inability to 
complete daily tasks.  Furthermore, the staggering treatment cost is worsened by 
ineffective therapeutic options that require lengthy treatment duration1.  In addition to 
being ineffective, current first-line therapeutics have harmful side effects such as 
opioid dependence, NSAID-induced gastrointestinal bleeding and hepatotoxicity 
(acetaminophen), highlighting the need for novel analgesic drug development2. 
 In order to develop more effective analgesic options, the underlying signaling 
mechanisms of pain pathology need to be thoroughly investigated to identify novel 
therapeutic targets.  However, the complexity of the nociceptive system makes this a 
difficult task; there are many causes of pain, each of which activates a variety of 
nociceptive pathways via multiple pronociceptive receptors and ion channels.  In 
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addition to the complexity of nociceptive pathway activation, the sensitization 
process that mediates chronic pain adds an additional level of complexity, occurring 
peripherally and/or centrally.  Recent analgesic drug discovery efforts targeting 
individual pronociceptive receptors have been plagued by lack of efficacy, most 
likely due to the diversity of receptors and pain modalities3.  One of the 
pronociceptive receptors recently targeted for analgesic drug development is the 
TRPV1 ion channel.  TRPV1 functions both as a noxious heat detector and as a pH 
sensor following nerve injury and inflammation, in which the pH decreases3.  
Notably, antagonists of TRPV1 exhibit reductions in hyperalgesia in preclinical 
models of chronic pain; however, when evaluated in human clinical trials, TRPV1 
antagonism results in severe hyperthermia.  This interference with TRPV1-mediated 
thermoregulation has prevented regulatory approval for the use of TRPV1 
antagonists as therapeutics in the clinic132, 133.  Other compounds that have showed 
modest efficacy in preclinical models include antagonists of prostanoid receptors 
which are activated by prostaglandin E2 during inflammation134, neurokinin-1 
receptor which is activated by substance P following injury and inflammation135, 
bradykinin 1 receptor which is activated during inflammation136 and tyrosine receptor 
kinase receptor A (TrkA) which is activated by nerve growth factor (NGF) following 
injury and inflammation137.  Unfortunately, antagonism of any of these receptors has 
yet to yield effective analgesics for use in humans.  Once again, lack of efficacy is 
likely due to the receptor diversity within the nociceptive system, the diversity of 
signaling mechanisms involved in each pain modality, and detrimental on-target 
effects on other physiological processes including cardiovascular function3, 134. 
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 A more recent approach to overcome issues with receptor diversity has been 
to focus on signaling proteins that are downstream of these receptors such as 
protein kinase C epsilon (PKCε) and mitogen-activated protein kinases (MAPKs).  
Although inhibitors of these kinases have exhibited reduced thermal hyperalgesia 
and mechanical allodynia in rodent models of chronic pain, their efficacy did not 
translate to use in humans55, 58, 59.  Furthermore, ubiquitous expression of these 
downstream effectors may limit their future use due to unwanted, on-target effects in 
other tissues. 
 This work aimed to characterize a novel molecular target in nociceptive 
neurons that could provide an exciting new direction for analgesic drug 
development, bypassing the inefficiency and adverse side effects of previous efforts.  
We used genetic approaches to characterize the role of PIP5K1C in nociceptive 
signaling and sensitization and developed a small molecule inhibitor to 
pharmacologically validate PIP5K1C as a novel target for analgesic drug 
development.  The major findings of this work are 1) PIP5K1C is a critical regulator 
of nociceptive signaling and sensitization, acting via synthesis of PIP2 which is at a 
critical convergence point for many pain promoting pathways, 2) development of a 
high-throughput assay identified the first reported inhibitor of PIP5K1C (UNC3230), 
an approach that could be extended to other novel kinases that modulate pain, 3) 
UNC3230 is a potent and selective inhibitor of PIP5K1C that reduces pronociceptive 
signaling similar in magnitude to reductions observed in a Pip5k1c haploinsufficiency 
model and 4) reductions in PIP5K1C catalytic activity, either via genetic or 
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pharmacological approaches, profoundly reduces thermal and mechanical 
nociceptive sensitization in multiple rodent models of chronic pain. 
The major implications of this work include the identification of a novel 
regulatory kinase in the complex nociceptive system, which will promote future 
studies of lipid kinases in nociceptive signaling, and the validation of PIP5K1C as an 
analgesic drug target, which provides the critical foundational work to guide future 
analgesic drug development.  Importantly, the restricted expression of PIP5K1C in 
neurons may eliminate many of the unwanted side effects observed with antagonism 
of other pronociceptive receptors and previously studied downstream effectors that 
are ubiquitously expressed.  In addition, PIP2 and PIP5K1C represent a central 
regulatory point for multiple pain promoting pathways, which could allow inhibitors of 
PIP5K1C to overcome issues of receptor and pathway diversity that have plagued 
previous analgesic drug development strategies.  
 
Key Findings 
This work provides the first evidence that PIP5K1C generates at least half of 
all PIP2 in DRG neurons.  Furthermore, PIP5K1C is an important regulator of 
nociceptive signaling and sensitization, including thermal and mechanical 
hypersensitivity in models of neuropathic and inflammatory pain1.  These 
conclusions are supported by experiments with Pip5k1c+/- mice and with a small 
molecule inhibitor of PIP5K1C.  Pip5k1c haploinsufficiency reduced PIP2 levels in 
adult DRG by ~50% without affecting PIP2 levels in adult brain or spinal cord making 
it unlikely that the observed antinociceptive phenotypes were due to Pip5k1c 
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haploinsufficiency in other regions of the nervous system.  Moreover, intrathecal 
delivery of a small molecule inhibitor, UNC3230, recapitulated these antinociceptive 
phenotypes, suggesting that localized inhibition of PIP5K1C in adults (and not during 
development) is sufficient to reduce nociceptive sensitization.        
We speculate that PIP2 levels were reduced in DRG of Pip5k1c+/- mice but not 
in spinal cord or brain because of a greater dependence on Pip5k1c in DRG relative 
to these other tissues.  In support of this hypothesis, PIP2 levels were not reduced in 
the brain of Pip5k1c+/- mice51, but were reduced by 50% in the brain of embryonic 
Pip5k1c-/- mice 51, 138.  Thus, PIP2 levels in the central nervous system appear to be 
insensitive to Pip5k1c haploinsufficiency.  Additionally, PIP2 levels were not reduced 
in the brain of embryonic Pip5k1a, Pip5k1b double knockout mice, suggesting other 
enzymes besides Pip5k1a, Pip5k1b, and Pip5k1c generate PIP2 in the nervous 
system 51.  This greater dependence on Pip5k1c in DRG makes PIP5K1C a 
particularly attractive target for analgesic drug development, as inhibition of 
PIP5K1C has the potential to lower PIP2 levels in sensory neurons without 
perturbing PIP2 levels in other cell types, including those in the brain.   
 
PIP5K1C modulates pronociceptive signaling and sensitization via PIP2-
dependent mechanism(s). 
GPCR- and TRVP1-evoked calcium signaling was significantly blunted in 
Pip5k1c+/- neurons.  Similarly, neuronal excitability that is mediated by PIP2-
dependent ion channels was significantly attenuated in Pip5k1c+/- neurons.  These 
data suggest that PIP2 required for PLC-catalyzed GPCR signaling and the direct 
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regulatory interactions of PIP2 with the C terminus of ion channels regulate at least 
three pronociceptive signaling pathways.  Likewise, these data suggest that 
PIP5K1C regulates these pathways via synthesis of PIP2.  PIP2-dependence was 
supported by complete restoration of signaling deficits (GPCR, TRPV1, and ion 
channel mediated) in Pip5k1c+/- neurons following exogenous delivery of PIP2.  
Consistent with these findings, others have demonstrated that exogenous PIP2 
delivery rescued histamine-evoked calcium responses in HeLa cells following 
Pip5k1c knockdown with small interfering RNA (siRNA) 41.  Additionally, ATP-evoked 
calcium release from purinergic receptors was significantly blunted in Pip5k1c+/- 
lateral nonsensory cells 52, further indicating that Pip5k1c regulates receptor 
signaling.     
 Pip5k1c regulates many additional processes downstream of PIP2, including 
actin dynamics, synaptic vesicle release and NMDA-induced AMPA receptor 
endocytosis 67, 131, 139, 140.  However, neurotransmission was not impaired between 
sensory neurons and spinal neurons in Pip5k1c+/- mice, making it unlikely that 
vesicle recycling deficits accounted for reduced behavioral sensitization.  In contrast, 
we did observe deficits in cytoskeletal (actin and tubulin) dynamics in Pip5k1c+/- 
neurons, indicating there are likely multiple PIP2-dependent processes contributing 
to the deficits in nociceptive signaling and sensitization.  Importantly, increases in 
tubulin expression in Pip5k1c+/- neurons could contribute to the reductions observed 
in TRPV1- and GPCR-mediated calcium signaling via tubulin-PIP2-PLC interactions.  
In fact, increases in tubulin levels inhibit PLC1β-mediated signaling, an important 
step in both GPCR and TRPV1 signaling29, 32.  Thus, it is likely that increases in 
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tubulin expression in Pip5k1c+/- neurons are partially responsible for the signaling 
deficits.  Furthermore, it is known that changes in actin and tubulin dynamics 
influence lipid bilayer properties and subsequently receptor stability and 
functionality33, 97, 139, and could be contributing to the observed signaling deficits in 
Pip5k1c+/- neurons.  Collectively, our data highlight the importance of PIP2 for 
efficient pronociceptive signaling and reveal that reductions in PIP5K1C lead to 
PIP2-dependent reductions in pronociceptive signaling; however, the exact 
mechanism by which this occurs requires further investigation. 
 Importantly, thermal and mechanical nociceptive sensitization in models of 
chronic inflammatory and neuropathic pain was enduringly blunted in Pip5k1c+/- mice 
in a PIP2-dependent manner.  This critical finding has significant implications for the 
field of pain signaling.  Discovery of novel regulatory proteins that mediate 
nociceptive sensitization allow for a more complete understanding of the complex 
sensitization process.  In addition, our findings will promote investigation of other 
lipid kinases that could be targeted to reduce nociceptive sensitization.  
Furthermore, our findings provided rationale to investigate PIP5K1C as a drug 
target, considering the fact that kinases are highly druggable targets141. 
 
PIP5K1C is a novel analgesic drug target  
The antinociceptive phenotypes in Pip5k1c+/- mice prompted the development 
of a high-throughput screen for PIP5K1C inhibitors.  From this screen, we identified 
UNC3230, a compound that inhibited PIP5K1C in the low nanomolar range and 
reduced receptor signaling and nociceptive sensitization in a fashion analogous to 
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Pip5k1c haploinsufficiency.  We evaluated the specificity of UNC3230 relative to a 
large panel of kinases and discovered that UNC3230 has remarkable selectivity for 
PIP5K1C and PIP4K2C, two lipid kinases that directly generate PIP2.  However, we 
cannot exclude the possibility that UNC3230 also inhibits kinases that we did not 
test, including additional kinases that generate PIP2.  Nevertheless, given that 
UNC3230 reduces PIP2 levels in cultured DRG neurons, our data suggest that 
UNC3230 has on-target biochemical effects.  
Our genetic and pharmacological data validate PIP5K1C as a therapeutic 
target for chronic pain; however, further optimization of hits from our high-throughput 
screen is needed.  For example, UNC3230 has a narrow efficacy window and 
solubility issues that limited our ability to perform dose-responses in vitro and in vivo.  
However, these shortcomings may be overcome through subsequent medicinal 
chemistry optimization.  PIP5K1C inhibitors could provide a valuable alternative to 
opioid and non-steroidal anti-inflammatory analgesics.  
PI5K1C is highly and somewhat selectively expressed in neuronal tissue (in 
addition to very minimal expression in the kidney) indicating that PIP5K1C inhibitors 
may bypass unwanted side effects that have plagued previous analgesic drug 
development focused on individual receptors and ubiquitously expressed 
downstream effectors55, 59, 88, 134, 135, 142.  Localized administration (intrathecal) of 
PIP5K1C inhibitors provides the greatest potential for mitigating on-target adverse 
effects given that renal function may be altered following systemic administration 
due to expression of PIP5K1C in the kidneys.  The main challenge for PIP5K1C 
inhibition as an orally available analgesic is prevention of blood-brain barrier (BBB) 
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penetration.  Compounds can be designed (based on UNC3230 or future scaffolds) 
that do not penetrate the BBB, which will restrict their activity to the peripheral 
nervous system and make the potential for an orally available PIP5K1C inhibitor with 
minimal on-target adverse effects very possible.  As mentioned previously, 
UNC3230 already exhibits excellent selectivity.  Most notably, UNC3230 does not 
inhibit human PIP5K1A (homologous to mouse PIP5K1B), which is ubiquitously 
expressed, further enhancing the potential for continued development of inhibitors 
with minimal adverse off-target effects. 
 
Implications for phosphoinositide signaling  
Our findings also could extend beyond PIP5K1C and promote research into 
additional enzymes lipid kinases, phosphatases, and lipid transporters that affect 
PIP2 levels in DRG neurons.  Indeed, a recent functional genomics study identified 
phospholipid signaling and lipid kinases as key regulators of heat nociception in flies 
143.  This study also found that Pip5k1a-/- mice displayed hypersensitivity to noxious 
heat and capsaicin.  However, Pip5k1a is expressed at much lower levels in DRG 
and does not contribute to PIP2 levels in the nervous system 51, so precisely how 
and where Pip5k1a regulates heat nociception in mice is unknown.  Given the 
sometimes differing or opposing roles of Pip5k1c and Pip5k1a in the same 
processes47, 48, 97, 144, 145, it is reasonable to speculate that Pip5k1c and Pip5k1a may 
have opposing functions in DRG neurons.  Furthermore, given the complexity of 
nociceptive signaling and the low level of expression of Pip5k1a in DRG neurons, 
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Pip5k1a could be modulating nociceptive processes at the level of the spinal cord or 
brain.   
Moreover, PIP5K1C inhibitors will likely have uses as tool compounds that will 
aid in studies of PIP5K1C in other processes such as endocytosis, synaptic vesicle 
trafficking, and focal adhesion dynamics.  Current methods to study these processes 
include obtaining primary neuron cultures from Pip5k1c-/- embryos or transiently 
transfecting PIP5K1C in common cell culture lines including human embryonic 
kidney (HEK) and HeLa cells41, 45, 131.  Obtaining primary neuron cultures from 
knockout mice is time and resource-intensive and only allows examination of this 
processes following deletion of the entire protein for an extended period of time, 
thwarting efforts to investigate transient inhibition of PIP5K1C catalytic activity.  Use 
of transient transfection in HEK or HeLa cells prevents studying the enzyme at 
physiologically relevant concentrations and tissue type (PIP5K1C is found primarily 
in neurons).  Transient inhibition of PIP5K1C with the identified small molecules will 
allow studies to determine which PIP5K1C-dependent processes are independent of 
or dependent upon catalytic activity48.  In addition, the identified inhibitors can be 
used as a complementary approach to genetic studies to differentiate between 
phenotypes that arise from chronic inhibition of the protein (genetic knockout mice) 
and acute inhibition of the catalytic activity (pharmacological transient inhibition).  
Lastly, characterization of the effects of PIP5K1C inhibition on phosphoinositide-
dependent processes outside of the nociceptive system is necessary to inform 
studies aimed at future development of these inhibitors as analgesics. 
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Homozygous deletion of PIP5K1C in sensory neurons reduces DRG nerve 
innervation into target tissue 
Although this was an unexpected finding, decreased nerve innervation in 
Pip5k1cfl/fl mice provides helpful insight into the role of PIP5K1C in DRG processes 
that are not part of the nociceptive system.  Interestingly, the phenotype observed in 
Pip5k1cfl/fl mice is different from previous reports of proprioceptive phenotypes.  
Although Pip5k1cfl/fl mice have the characteristic reductions in nerve innervation that 
accompany proprioceptive phenotypes that have been reported in the literature, 
elimination of parvalbumin positive neurons that are critical for proprioceptive 
function was not observed in Pip5k1cfl/fl mice101, 102.  These data indicate the 
mechanism of reduced nerve innervation in Pip5k1cfl/fl mice differs from other 
reported phenotypes.  Furthermore, it indicates that homozygous deletion of Pip5k1c 
does not result in the observed phenotypes due to a loss of neurons within the DRG; 
rather, the phenotype most likely arises from a global inability of DRG neurons to 
extend their axons into the peripheral tissue.   
Given the observed cytoskeletal alterations and receptor-mediated signaling 
deficits in Pip5k1c+/- mice, it is reasonable to expect that Pip5k1cfl/fl mice would also 
exhibit these defects.  We speculate that if signaling deficits of Pip5k1cfl/fl mice are 
similar to or more pronounced than those observed with Pip5k1c+/- mice, it is likely 
that PIP2-dependent Trk receptors that mediate neurotrophin axonal guidance for 
innervation are contributing to the observed phenotype.  Furthermore, we speculate 
that if actin and tubulin defects of Pip5k1cfl/fl mice are similar to or more pronounced 
than those observed with Pip5k1c+/- mice, these deficits are likely contributing to the 
  
132 
observed phenotype given that concerted cytoskeletal rearrangement is required for 
axon innervation.  Additional characterization of Pip5k1cfl/fl mice is needed to fully 
elucidate the mechanism(s) responsible for the proprioceptive phenotype.  It is 
important to note that nerve innervation deficits are likely due to chronic reductions 
in PIP5K1C and PIP2 during embryonic development.  However, experiments with 
inducible conditional knockout mice (homozygous deletion of PIP5K1C in adult mice) 
are needed to confirm that deletion of PIP5K1C during development is the cause of 
the proprioceptive phenotype.  We speculate that deleting PIP5K1C in adults (using 
an inducible Cre) will not result in a proprioceptive phenotype.  Given that PIP5K1C 
inhibitors are administered to adult mice and that nerve innervation deficits are most 
likely a result of reduced PIP5K1C during embryonic development, alterations in 
nerve innervation following administration of small molecule PIP5K1C is unlikely.  
However, experiments to evaluate nerve innervation following inhibitor treatment are 
needed.   
Characterization of conditional heterozygous mice, Pip5k1cfl/wt, is currently 
ongoing to test our original hypothesis that reductions in PIP5K1C synthesis of PIP2 
in the DRG are responsible for the antinociceptive phenotypes observed in 
Pip5k1c+/- mice.  We hypothesize that conditional deletion of one allele of PIP5K1C 
will reduce PIP2 in the DRG by at least 50%, the level of reduction observed in 
Pip5k1c+/- mice, and attenuate nociceptive signaling and sensitization in a similar 
manner to the reductions observed in Pip5k1c+/- mice.  
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Human implications 
Humans heterozygous for a mutation in PIP5K1C that results in a non-
functional protein develop normally and appear healthy94.  Since humans can clearly 
tolerate a life-long reduction in PIP5K1C gene dosage, drugs that transiently inhibit 
PIP5K1C have the potential to be well tolerated with chronic use.  While loss of high 
frequency hearing was observed in Pip5k1c+/- mice, this is not likely to be an issue in 
humans since humans cannot hear above 20 kHz146. In contrast to the benign 
heterozygous mutation, humans carrying two non-functional PIP5K1C alleles 
(homozygous mutation), develop lethal congenital contracture syndrome type 3 
(LCCS3), which is characterized by muscle atrophy, joint contractures and death 
within 24 hours of birth94.  The lethality of the human phenotype closely mimics the 
perinatal lethality observed in the Pip5k1c-/- mice 45; although, the link between 
reduced PIP2 and the characteristic joint contractures and muscle atrophy in the 
human disease has not been determined.  The exact cause of lethality in the 
knockout mice generated by Di Paolo et al. 45 was never investigated; however, the 
gene trap knockout mice that resulted in embryonic lethality generated by Wang et 
al138 revealed cardiovascular and neuronal abnormalities that were mediated by 
deficits in actin-dependent processes in cardiomyocytes and neuroepithelium.  
Wang et al and Di Paolo et al published their findings prior to the report of PIP5K1C 
mutations in LCCS3 by Narkis, et. Al. and thus no insights were provided on the 
murine findings and the link to the characteristics of the human phenotype.  
Interestingly, the data from our studies and from Wang, et. al. supports the 
hypothesis that the interaction between PIP2 and cytoskeletal proteins such as actin 
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and tubulin is the critical link between PIP5K1C mutations and the human 
phenotype.  
Our data with Pip5k1c+/- mice reveal a critical role of PIP2 in regulating 
physiological actin and tubulin dynamics,27 two key components of muscle 
contraction that promote muscle contraction, strength, and force147, 148. In addition to 
the altered expression pattern of actin and the increase in tubulin expression, RNA 
sequencing of DRG from Pip5k1c+/- mice revealed more than 2-fold increases in 
several troponin T mRNAs compared to WT controls.  It is reasonable to speculate 
that these changes in cytoskeletal mRNAs may serve as a compensatory 
mechanism for the loss of PIP2 interactions with actin and tubulin once PIP5K1C 
expression is reduced.  However, analysis of protein expression of these 
cytoskeletal filaments is still needed.  Although our analysis was completed with 
DRG neurons, it is possible that these changes may occur in the muscle as well.  
Although PIP5K1C expression is thought to be restricted to neuronal tissues in mice, 
the expression profile of PIP5K1C in humans has not been determined.  
Furthermore, PIP5K1C is minimally expressed in murine skeletal muscle (expression 
in smooth muscle has never been investigated)45.  Furthermore, alterations in actin 
and tubulin would likely decrease nerve innervation of alpha motor neurons into the 
muscle (as observed when conditionally deleting PIP5K1C).  Even if there were no 
changes in expression levels of cytoskeletal proteins involved in muscle contraction, 
the mislocalization of actin observed would likely be enough to alter contractibility 
given that actin serves as the scaffold for myosin, tropomyosin, and troponin 
interactions that result in contraction148-150.  Indeed, disruption of the actin 
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cytoskeleton with cytochalasin B reduced contractile speed149.  Collectively, our data 
suggests a link between reduced PIP2 synthesis and alterations in cytoskeletal 
proteins that may explain the LCCS3 phenotype in humans.  In fact, mutations in 
genes that encode thin-filament proteins including actin and troponin T result in 
skeletal myopathies similar to LCCS396.  Although our data provides a suggestive 
link between PIP5K1C reductions of PIP2 and the muscle/joint phenotypes of 
LCCS3, additional studies are required to determine the expression profile of 
PIP5K1C in humans and the extent to which cytoskeletal genes and proteins are 
expressed in humans carrying homozygous mutations in PIP5K1C. 
Importantly, there are no reported muscle contraction/atrophy phenotypes 
reported in humans carrying a heterozygous mutation of PIP5K1C.  Furthermore, as 
mentioned above, heterozygous mutations in PIP5K1C are well tolerated in humans 
making it likely that PIP5K1C analgesics would be well tolerated.  Thus, we conclude 
that although our preliminary studies with actin and tubulin provide a suggestive link 
between homozygous mutation in PIP5K1C and the muscle contracture phenotype, 
it is unlikely that LCCS3-like symptoms would arise from acute administration of 
PIP5K1C analgesics in the adult.  In support of this conclusion, there were no 
phenotypes similar to those in LCCS3 observed in Pip5k1c+/- mice or following 
administration of UNC3230.  Moreover, the LCCS3 phenotype is likely due to 
reduced PIP2 synthesis during embryonic development, further supporting our 
hypothesis that LCCS3-like phenotypes would not result from small molecule 
inhibition in adults.  Development of more effective inhibitors (>50% reduction in 
PIP2 synthesis) and/or investigation of Pip5k1c conditionally deleted during 
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adulthood only (inducible conditional knockout mice) are needed to provide more 
conclusive evidence that the nerve innervation phenotype (Chapter III) and LCCS3 
human phenotype are a result of PIP5K1C loss during development.  In addition, 
delivery of PIP5K1C-targeted analgesics could be (and have been) limited to the 
spinal region, eliminating all concerns that could arise from PIP5K1C inhibition within 
the muscle or other tissues.  Our studies with Pip5k1c+/- mice and UNC3230 indicate 
that a 50% reduction in PIP2-synthesis is sufficient to attenuate nociceptive signaling 
and sensitization, thus complete loss of PIP5K1C function would not be required for 
effective analgesic activity.  Development of a more effective PIP5K1C inhibitor that 
would abrogate PIP2 levels and mimic the complete loss of PIP5K1C activity that 
results from homozygous mutation is needed to evaluate the full analgesic potential 
of PIP5K1C inhibitors and the risk of developing muscle contracture phenotypes. 
It is currently unknown if humans with homozygous mutations of PIP5K1C 
have reduced inflammatory pain responses, such as those found in Pip5k1c+/- mice.  
Importantly, future studies with these human carriers have the potential to directly 
assess the importance of PIP5K1C in human pain perception.  Lastly, individuals 
that carry one non-functional allele of PIP5K1C are Bedouins and live in the Negev 
desert of Israel—an environment that is arid and subject to extreme temperatures.  
Like sickle-cell anemia, where heterozygotes have a survival advantage in regions 
where malaria is endemic, mutations in PIP5K1C could provide a survival advantage 
in the desert, where somatosensory stimuli can be extreme.  Although this is 
suggestive of a link between the observed phenotypes in Pip5k1c+/- mice and 
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humans carrying PIP5K1C heterozygous mutations, further characterization is 
needed to implicate the pathway in humans. 
 
Conclusions 
The aim of this dissertation was to rigorously characterize the role of 
PIP5K1C, a potentially druggable kinase, in nociceptive signaling and sensitization.  
To accomplish this aim we utilized two approaches in parallel, genetic deletion of the 
Pip5k1c (Pip5k1c+/- knockout mice) and pharmacological (small molecule) inhibition 
of PIP5K1C.  Completion of this work revealed a central regulatory role of PIP5K1C 
in GPCR- and ion channel-mediated pronociceptive signaling.  Similarly, PIP5K1C 
regulates nociceptive sensitization in models of neuropathic and inflammatory 
chronic pain.  Our work with Pip5k1c+/- mice identified a novel regulatory mechanism 
that will influence future studies of the nociceptive system and has the potential to 
prompt studies of pain perception in humans that carry a heterozygous mutation in 
PIP5K1C.  In addition, a novel PIP5K1C high-throughput screen identified the first 
reported PIP5K1C inhibitor, which has broad implications for the field of 
phosphoinositide signaling and analgesic drug development.    
APPENDIX 1:  PERSONAL CONTRIBUTIONS TO DISSERTAITON CHAPTERS 
 With guidance from Dr. Mark Zylka, I completed all experiments and analyzed 
all data in Chapters II and III with the following exceptions.  For Chapter II, Megumi 
Aita at the UNC in situ hybridization core performed the double fluorescence in situ 
hybridization using probes prepared by members of Dr. Mark Zylka’s laboratory 
(Figure 2.1D-E).  Bonnie Taylor-Blake completed all immunohistochemical staining 
(Figures 2.1F-G and 2.11A-J).  Dr. Sarah Street completed all electrophysiological 
studies (experimentation and analysis; Figures 2.6A-B and 2.11K-N).  Walter Dutton 
performed behavioral experiments using the LPA-induced neuropathic pain model 
(Figure 2.9A-B).  Dr. Eric McCoy performed the light touch mechanical sensitivity 
assay (Figure 2.10D) and the UNC Behavioral Phenotyping Core completed the 
rotarod studies (Figure 2.10A).  For Chapter III, Bonnie Taylor-Blake completed all 
immunohistochemical analysis of hindpaw glabrous skin, volar pad, and hairy skin 
(Figure 3.5). 
 For Chapter IV, I completed all assay development, primary screening, and 
data analysis with guidance from Cathy Simpson and William Janzen.  The UNC 
CICBDD provided the LOPAC and kinase-focused libraries for screening.  Chatura 
Jayakody prepared all screening plates.  Michael Stashko completed selectivity 
screening of 48 kinases using the ProfilerPro platform.  Selectivity screening of 100 
kinases was completed at DiscoveRx and Dan Lockhart generated the KinomeTree 
diagram using DiscoveRx software.  Dr. Anqi Ma synthesized large quantities of 
UNC3230 for testing in vitro and in vivo. 
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